VSee Health has $41.7K cash, flags going-concern doubt
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
VSee Health, Inc. (VSEE), which provides telehealth physician services through iDoc, reported nine-month continuing-operations revenue of $4.94 million, versus $4.57 million a year earlier. Cost of revenue rose to $3.69 million from $2.01 million, and the continuing-operations net loss widened to $7.19 million from $5.59 million. Third-quarter revenue was $1.50 million, down from $2.32 million, and quarterly net loss was $2.85 million versus $289,745.
Cash was $41,666 at September 30, while operating cash outflow from continuing operations was $3.00 million for the nine months. Management said liquidity and historical losses raise substantial doubt about the company’s ability to continue as a going concern for at least one year after issuance of the statements. It is negotiating additional financing, but said there is no assurance its plans will succeed.
VSee Health sold VSee Lab on May 31, 2026, to Milton Chen, its former co-CEO and chairman, and recorded a $4.17 million gain on the discontinued operation. It also reported three notes in default for late payment, with balances of $1.50 million, $33,000 and $64,000.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Major pointVSee Lab sale generated a $4.17 million gain on discontinued operations.
- Moderate pointNine-month continuing-operations revenue rose to $4.94 million from $4.57 million.
Negative
- Major pointManagement disclosed substantial doubt about continuing as a going concern for at least one year.
- Major pointNine-month continuing-operations loss widened to $7.19 million from $5.59 million.
- Major pointThree notes with balances of $1.50 million, $33,000 and $64,000 were in default for late payment.
- Moderate pointThird-quarter revenue fell to $1.50 million from $2.32 million.
Filing Explained
VSee Health agreed to acquire about
Key Figures
Key Terms
going concern financial
discontinued operations financial
allowance for credit losses financial
original issue discount financial
SEPA liability financial
reverse stock split financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue did VSEE report for the first nine months of 2026?
Which VSEE notes were in default for late payment?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
For the quarterly period
ended
or
For the transition period from to
Commission File Number:
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) | (I.R.S.
Employer Identification Number) |
(Address of Principal Executive Offices)
(
(Registrant’s telephone number)
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading symbol | Name of Exchange on which registered | ||
| OTC | ||||
| OTC |
Indicate by check mark
whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of
the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such filing requirements for
the past 90 days.
Indicate by check mark
whether the registrant has submitted electronically every Interactive Data File required to be submitted
pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding
12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large, accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large, accelerated filer | ☐ | Accelerated filer | ☐ | ||
| ☒ | Smaller reporting company | ☒ | Emerging growth company |
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act.
Indicate by check mark
whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act). Yes ☐ No
As of November 15, 2026, there were
TABLE OF CONTENTS
| Page | |||
| Part I | Financial Information | 1 | |
| Item 1. | Financial Statements | 1 | |
| Condensed Consolidated Balance Sheets as of September 30, 2026 (Unaudited) and December 31, 2025 | 1 | ||
| Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2026 and 2025 (Unaudited) | 2 | ||
| Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the three and nine months ended September 30, 2026 and 2025 (Unaudited) | 3 | ||
| Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 and 2025 (Unaudited) | 5 | ||
| Notes to Condensed Consolidated Financial Statements (Unaudited) | 6 | ||
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 43 | |
| Item 3. | Quantitative and Qualitative Disclosures about Market Risk | 50 | |
| Item 4. | Controls and Procedures | 50 | |
| Part II | Other Information | 52 | |
| Item 1. | Legal Proceedings | 52 | |
| Item 1A. | Risk Factors | 52 | |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 52 | |
| Item 3. | Defaults Upon Senior Securities | 53 | |
| Item 4. | Mine Safety Disclosures | 53 | |
| Item 5. | Other Information | 53 | |
| Item 6. | Exhibits | 53 | |
| Exhibit Index | 53 | ||
| Signatures | 54 | ||
i
Table of Contents
As used in this Quarterly Report on Form 10-Q, unless otherwise indicated, VSee Health, Inc., together with its consolidated subsidiaries, is hereinafter referred to as “VSee Health,” the “Registrant,” “us,” “we,” “our” or the “Company.”
Cautionary Note on Forward-Looking Statements
This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements appear in a number of places in this Form 10-Q including, without limitation, in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements are typically identified by words such as “plan,” “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “should,” “would” and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking.
The forward-looking statements are based on the current expectations of our management and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statement. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may These risks and uncertainties include, but are not limited to, those factors described in “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, filed by us with the Securities and Exchange Commission (“SEC”).
These and other factors could cause actual results to differ from those implied by the forward-looking statements. Forward-looking statements are not guarantees of performance and speak only as of the date hereof. The forward-looking statements are based on the current and reasonable expectations of our management but are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statements. There can be no assurance that future developments will be those that have been anticipated or that we will achieve or realize these plans, intentions or expectations.
All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
In addition, statements of belief and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this filing, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.
ii
Table of Contents
PART I —FINANCIAL INFORMATION
Item 1. Financial Statements
VSEE HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
| September 30, 2026 | December 31, 2025 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash | $ | $ | ||||||
| Accounts receivable, net of allowance for credit losses of $ | ||||||||
| Due from related party | ||||||||
| Prepaids and other current assets | ||||||||
| Current assets from discontinued operations | ||||||||
| Total current assets | ||||||||
| Non-current assets | ||||||||
| Long-term investments | ||||||||
| Right-of-use assets, net | ||||||||
| Intangible assets, net | ||||||||
| Goodwill | ||||||||
| Fixed assets, net | ||||||||
| Non-Current assets from discontinued operations | ||||||||
| Total assets | $ | $ | ||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued liabilities | $ | $ | ||||||
| Due to related party | ||||||||
| Operating lease liabilities | ||||||||
| Financing lease liabilities | ||||||||
| Encompass Purchase Liability | ||||||||
| Convertible notes | ||||||||
| Loan payable, related party, net of discount | ||||||||
| Line of credit | ||||||||
| Notes payable, net of discount | ||||||||
| Common stock issuance obligation | ||||||||
| Current liabilities from discontinued operations | ||||||||
| Total current liabilities | ||||||||
| Non-current liabilities | ||||||||
| Notes payable, less current portion, net of discount | ||||||||
| SEPA liability | ||||||||
| Operating lease liabilities, less current portion | ||||||||
| Deferred tax liabilities, net | ||||||||
| Total liabilities | $ | $ | ||||||
| Commitments and Contingencies (Note 11) | ||||||||
| STOCKHOLDERS' EQUITY | ||||||||
| Preferred stock, par value $ | ||||||||
| Series A Preferred stock, $ | ||||||||
| Series B Preferred stock, $ | ||||||||
| Common stock, $ | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total stockholders' equity | ||||||||
| Total liabilities and stockholders’ equity | $ | $ | ||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements
1
Table of Contents
VSEE HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026, AND 2025 (UNAUDITED)
| For the Three Months Ended | For the Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenues | ||||||||||||||||
| Patient fees | $ | $ | $ | $ | ||||||||||||
| Telehealth fees | ||||||||||||||||
| Institutional fees | ||||||||||||||||
| Total revenues | ||||||||||||||||
| Cost of revenues | ||||||||||||||||
| Gross margin | ||||||||||||||||
| Operating expenses | ||||||||||||||||
| Compensation and related benefits | ||||||||||||||||
| General and administrative | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Net operating loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other income (expense) | ||||||||||||||||
| Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other income (expense), net | ( | ) | ||||||||||||||
| Change in fair value of financial instruments | ( | ) | ( | ) | ||||||||||||
| (Loss)/Gain on extinguishment of financial liabilities | ( | ) | ( | ) | ||||||||||||
| Loss on issuance of financial instruments | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Total other income (expense), net | ( | ) | ( | ) | ( | ) | ||||||||||
| Loss from continuing operations before provision for income taxes | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Provision for income taxes for continuing operations | ( | ) | ( | ) | ||||||||||||
| Loss from continuing operations, net of tax | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| (Loss) income from discontinued operations before provision for income taxes | ( | ) | ( | ) | ||||||||||||
| Provision for income taxes for discontinuing operations | ( | ) | ( | ) | ||||||||||||
| (Loss) income from discontinued operations, net of tax | $ | $ | ( | ) | $ | $ | ( | ) | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Basic and diluted loss per common share- continuing operations | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Basic and diluted loss per common share | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted average number of common shares outstanding, basic and diluted - continuing operations * | ||||||||||||||||
| Weighted average number of common shares outstanding, basic and diluted | ||||||||||||||||
| * |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
2
Table of Contents
VSEE HEALTH, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT) *
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026
| Series A Preferred Stock | Series B Preferred Stock | Common Stock | Additional Paid- | Accumulated | Total Stockholders' | |||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | In Capital | Deficit | Equity | ||||||||||||||||||||||||||||
| Balance - December 31, 2025 | $ | - | $ | - | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||||
| Net loss for the three months ended March 31, 2026- Continuing operations | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||
| Net loss for the three months ended March 31, 2026- Discontinued operations | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||
| Shares issued on the exercise of pre-funded warrants | - | - | - | - | - | |||||||||||||||||||||||||||||||
| Shares issued on conversion of preferred stock | ( | ) | - | - | - | ( | ) | - | - | |||||||||||||||||||||||||||
| Shares issued as part of stock grants to vendors | - | - | - | |||||||||||||||||||||||||||||||||
| Stock based compensation | - | - | - | - | - | |||||||||||||||||||||||||||||||
| Shares issued during the period | - | - | - | - | - | |||||||||||||||||||||||||||||||
| Balance - March 31, 2026 | $ | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||||||
| Net loss for the three months ended June 30, 2026- Continuing operations | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||
| Net income for the three months ended June 30, 2026- Discontinued operations | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||
| Shares issued on conversion of Series A preferred stock | ( | ) | - | - | - | - | - | - | - | |||||||||||||||||||||||||||
| Shares issued on conversion of Series B preferred stock | - | - | ( | ) | ( | ) | ( | ) | - | - | ||||||||||||||||||||||||||
| Repurchase of common stock in connection with sale of VSee Labs (Refer Note 3) | - | - | - | - | ( | ) | ( | ) | ( | ) | - | ( | ) | |||||||||||||||||||||||
| Shares issued on conversion of Quantum loan | - | - | - | - | - | |||||||||||||||||||||||||||||||
| Shares issued on exercise of pre - funded warrants | - | - | - | - | - | |||||||||||||||||||||||||||||||
| Stock based compensation | - | - | - | - | - | |||||||||||||||||||||||||||||||
| Balance - June 30, 2026 | $ | - | $ | - | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||||
| Net loss for the three months ended September 30, 2026- Continuing operations | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||
| Shares issued on settlement of ADI convertible note | - | - | - | - | - | |||||||||||||||||||||||||||||||
| Shares issued on settlement of M2B convertible note | - | - | - | - | - | |||||||||||||||||||||||||||||||
| Shares issued as commitment fees to Strata SEPA liability (Refer Note 9) | - | - | - | - | - | |||||||||||||||||||||||||||||||
| Shares issued to vendor | - | - | - | - | - | |||||||||||||||||||||||||||||||
| Balance - September 30, 2026 | $ | - | $ | - | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||||
| * |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
3
Table of Contents
VSEE HEALTH, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT) *
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025
| Series A Preferred Stock | Series B Preferred Stock | Common Stock | Additional Paid- | Accumulated | Total Stockholders' | |||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares* | Amount | In Capital | Deficit | Deficit | ||||||||||||||||||||||||||||
| Balance - December 31, 2024 | $ | - | $ | - | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||
| Net loss for the three months ended March 31, 2025- Continuing operations | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||
| Net loss for the three months ended March 31, 2025- Discontinued operations | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||
| Payment to shareholder | - | - | - | - | - | - | ( | ) | - | ( | ) | |||||||||||||||||||||||||
| Issuance during the period | - | - | - | - | - | - | ||||||||||||||||||||||||||||||
| Share based compensation | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||
| Balance - March 31, 2025 | $ | - | $ | - | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||
| Net loss for the three months ended June 30, 2025- Continuing operations | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||
| Net loss for the three months ended June 30, 2025- Discontinued operations | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||
| Issuance during the period | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||
| Share based compensation | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||
| Balance - June 30, 2025 | $ | - | $ | - | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||
| Net loss for the three months ended September 30, 2025- Continuing operations | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||
| Net loss for the three months ended September 30, 2025- Discontinued operations | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||
| Issuance during the period | - | - | - | - | - | |||||||||||||||||||||||||||||||
| Balance - September 30, 2025 | $ | - | $ | - | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||
| * | Shares outstanding have been restated for the 1-for-80 reverse stock split effective September 22, 2026. See Note 2 – “Summary of Significant Accounting Policies”. |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
4
Table of Contents
VSEE HEALTH, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026
| For the Nine Months Ended | ||||||||
| September 30, | ||||||||
| 2026 | 2025 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Less: Net (income)/loss from discontinued operations | ( | ) | ||||||
| Net loss from continuing operations | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss from continuing operations to net cash used in operating activities: | ||||||||
| Allowance for expected credit losses | ||||||||
| Depreciation and amortization | ||||||||
| Stock-based compensation | ||||||||
| Amortization of right-of-use assets | ||||||||
| Loss on issuance of financial instruments | ||||||||
| Change in fair value of financial instruments | ( | ) | ||||||
| (Gain)/Loss on extinguishment of financial liabilities | ( | ) | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | ( | ) | ( | ) | ||||
| Due from related party | ( | ) | ||||||
| Prepaids and other current assets | ( | ) | ||||||
| Accounts payable and accrued liabilities | ||||||||
| Operating lease liabilities | ( | ) | ( | ) | ||||
| Net cash used in operating activities - continuing operations | ( | ) | ( | ) | ||||
| Net cash used in operating activities - discontinued operations | ( | ) | ( | ) | ||||
| Net cash used in operating activities | $ | ( | ) | $ | ( | ) | ||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Purchase of fixed assets | ( | ) | ||||||
| Purchase of long-term investments | ( | ) | ||||||
| Net cash used in investing activities - continuing operations | ( | ) | ||||||
| Net cash used in investing activities - discontinued operations | ( | ) | ( | ) | ||||
| Net cash used in investing activities | $ | ( | ) | $ | ( | ) | ||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Repayment of notes payable | ( | ) | ( | ) | ||||
| Proceeds from notes issued during the period | ||||||||
| Payments on factoring payable | ( | ) | ||||||
| Payment to shareholder | ( | ) | ||||||
| Proceeds from issuance of common stock | ||||||||
| Proceeds from pre-funded warrants, net of issuance costs | ||||||||
| Proceeds from convertible notes issued during the period | ||||||||
| Payments due on acquisition purchase | ( | ) | ||||||
| Payments on financing lease liability | ( | ) | ( | ) | ||||
| Payments on Encompass Purchase liability | ( | ) | ||||||
| Repayment of line of credit | ( | ) | ||||||
| Net cash (used in) provided by financing activities- continuing operations | ( | ) | ||||||
| Net cash used in financing activities- discontinued operations | ||||||||
| Net cash (used in) provided by financing activities | $ | ( | ) | $ | ||||
| NET CHANGE IN CASH | ( | ) | ||||||
| Cash, Beginning of Period | ||||||||
| CASH, END OF THE PERIOD | $ | $ | ||||||
| Supplemental disclosure of cash flow information: | ||||||||
| Cash paid for interest expense | $ | $ | ||||||
| Cash paid for income taxes | $ | $ | ||||||
| Non-cash investing and financing activities: | ||||||||
| Common stock issued on conversion of May 2025 Convertible Note | $ | $ | ||||||
| Common stock issued on conversion of Quantum note | $ | $ | ||||||
| Common stock issued to settle directors’ compensation payable | $ | $ | ||||||
| Common stock issued to settle executives’ compensation payable | $ | $ | ||||||
| Common stock issued to settle employees and consultants’ compensation payable | $ | $ | ||||||
| Common stock issued as consideration for investment in GoMyRx Inc. | $ | $ | ||||||
| Common and preferred stock issued to settle accounts payable | $ | $ | ||||||
| Common stock issued to ADI under the settlement agreement | $ | $ | ||||||
| Common stock issued to M2B under the settlement agreement | $ | $ | ||||||
| Promissory note issued to ADI under the settlement agreement | $ | $ | ||||||
| Promissory note issued to M2B under the settlement agreement | $ | $ | ||||||
| Common stock issued to settle commitment fees of Strata SEPA liability | $ | $ | ||||||
| Repurchase and cancellation of common stock on disposal of subsidiary | $ | $ | ||||||
| Assignment of loan to settle Encompass Purchase Liability | $ | $ | ||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
5
Table of Contents
VSEE HEALTH, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(all amounts in USD, except number of shares and per share data)
Note 1 Organization and Description of Business
VSee
Health, Inc., (formerly known as Digital Health Acquisition Corp., a Delaware Corporation) (the
“Company”, “we”, “our”, “VSee Health” or “us”) is
a Delaware-based telehealth software company that provides tele-critical care and tele-neurology physician
services to hospital systems, long-term acute care (LTAC) facilities, correctional facilities and other
customers through its wholly owned subsidiary, iDoc Virtual Telehealth Solutions, Inc. ("iDoc"), using iDoc's
internally developed telehealth technology platform. The Company earns revenue from telehealth fees and
patient fees and operates as
The Company was formed in Delaware on March 30, 2021, under the name Digital Health Acquisition Corp. (“DHAC”) as a “blank check company” for the purpose of acquiring, through a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, recapitalization or other similar business transaction, one or more operating businesses or assets. On June 24, 2024 (the “Closing Date”), the parties consummated the business combination by and among DHAC, DHAC Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of DHAC (“Merger Sub I”), DHAC Merger Sub II, Inc., a Texas corporation and a direct, wholly owned subsidiary of DHAC (“Merger Sub II”), VSee Lab Inc., a Delaware corporation (“VSee Lab”), and iDoc Virtual Telehealth Solutions, Inc., a Texas corporation (“iDoc”), (the “Business Combination”). In connection with the Business Combination, DHAC changed its name from Digital Health Acquisition Corp. to VSee Health, Inc. Furthermore, unless otherwise stated or unless the context otherwise requires, references to “DHAC” refer to Digital Health Acquisition Corp., a Delaware corporation, prior to the Closing Date. The transaction was accounted for as a reverse recapitalization, with VSee Lab, Inc. identified as the accounting acquirer.
iDoc, provides high-acuity patient care solutions through elite physician services in ICUs using a proprietary technology platform. It delivers neuro-critical care and tele-critical care services to a wide range of customers, including hospital systems, LTACs, and correctional facilities. Staffed by board-certified intensivists, neurointensivists, neurologists, and advanced practice providers, iDoc offers 24/7 care for acute neurological conditions and supports multidisciplinary treatment plans. Its services include teleneurocritical care, teleneurology, epileptology, and advanced monitoring such as intracranial pressure, cerebral hemodynamics, brain oximetry, microdialysis, and continuous EEG.
VSee Lab, was a telehealth software platform offering a scalable, API-driven solution for virtual healthcare delivery. Its proprietary, modular system enables plug-and-play telehealth services with end-to-end encrypted video, integrated with medical devices, EMRs, and other sensitive data (See Note 3 – Discontinued Operations).
For financial reporting purposes, historical financial data prior to June 24, 2024, reflects the operations of VSee Lab, Inc. The acquisition of iDoc Virtual Telehealth Solutions, Inc. was treated as a business combination under Accounting Standards Codification 805, Business Combinations, with the excess purchase consideration recorded as goodwill.
On
May 31, 2026, the Company divested VSee Lab by selling
Going Concern
Management has determined that principal conditions including the Company’s liquidity condition and historical operating losses raise substantial doubt about the Company’s ability to continue as a going concern for a period of time of at least one year after the date that the accompanying consolidated financial statements are issued.
The
Company has incurred multiple years of losses resulting in an accumulated deficit of $
Management has undertaken a series of measures to address these concerns, which include:
| ● | Revenue Enhancement Strategies: The Company won new contracts with larger hospitals and entered new markets, demonstrating the Company’s ability to generate positive revenue growth from its robust pipeline. | |
| ● | Additional Financing: The Company is in negotiations with an investor for additional financing, which is expected to support its working capital needs and fund its growth initiatives. |
There is no assurance that the Company’s plans to alleviate such concerns will be successful within one year after the date the condensed consolidated financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
6
Table of Contents
Note 2 Summary of Significant Accounting Policies
Basis of Presentation and Consolidation
The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.
The
unaudited condensed consolidated financial statements include the accounts of VSee Health, Inc. and its wholly
owned subsidiary, iDoc Virtual Telehealth Solutions, Inc. ("iDoc"). In addition, the consolidation includes
Encompass Healthcare Billing, LLC, a wholly owned subsidiary of iDoc. All intercompany balances and
transactions have been eliminated in consolidation. On May 31, 2026, the Company divested VSee Lab, Inc.
through the sale of its entire ownership interest. As a result, VSee Lab and its subsidiary, This American
Doc, Inc., are no longer included in the Company’s consolidated financial statements subsequent to the
divestiture date. Prior to June 24, 2024, the historical financial statements reflected the accounts of VSee
Lab, Inc. and its
The interim results for the three and nine months ended September 30, 2026, are not necessarily indicative of the results to be expected for the year ending December 31, 2026, or for any future interim periods. These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC. The significant accounting policies and estimates used in preparing these unaudited condensed consolidated financial statements were applied on a basis consistent with those used in the audited consolidated financial statements for the year ended December 31, 2025.
The results of operations, cash flows, and assets and liabilities of VSee Lab for prior periods have been recast and presented as discontinued operations (see Note 3 – Discontinued Operations). This presentation change did not impact the Company's consolidated net loss, consolidated cash flows, total assets, total liabilities or total stockholders' equity.
Segments
The Company identifies its operating segments in accordance with ASC 280, Segment Reporting ("ASC 280"), based on how its chief operating decision maker ("CODM") reviews financial information to assess performance and allocate resources.
Management has determined that the Company has one operating and reportable segment. The Company's segment reflects the manner in which its Chief Executive Officer, who serves as the Chief Operating Decision Maker ("CODM"), reviews results and allocates resources.
The Company’s operating and reporting segment is Telehealth Services (“Telehealth”). iDoc Virtual Telehealth Solutions, Inc. is included in Telehealth. Prior to the divestiture of VSee Lab on May 31, 2026, the Company's operations included a Healthcare Technology business. Following the disposition of VSee Lab, the Company no longer conducts Healthcare Technology operations, and the results of continuing operations is reported through the Telehealth segment.
Use of Estimates
The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts stated in the condensed consolidated financial statements and accompanying notes. These judgments, estimates, and assumptions are used for, but not limited to, the determination of estimated provision for contractual adjustments from third-party payors in the recognition of patient fee contracts, revenue, cost of revenues, goodwill and intangible asset impairment analysis, allowance for credit losses, ADI Promissory Note, M2B Promissory Note, the ADI Funding Convertible Note, ClearThink Convertible Note, Labrys Convertible Promissory Note (each of these instruments are defined in Note 8 Convertible notes), June 2026 SEPA liability, Strata SEPA liability (each of these are defined in Note 9 SEPA liability), stock-based compensation, incremental borrowing rate determination, useful life of intangibles, reserve for income tax uncertainties and other contingencies, and valuation of deferred tax asset.
The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. However, future events are subject to change and best estimates and judgments routinely require adjustment. Actual results could differ from those estimates.
Reverse Stock Split
On September 22, 2026, the Company implemented a 1-for-80 reverse split on outstanding shares of common stock. All share and per share data throughout these consolidated financial statements have been retroactively adjusted to reflect the reverse stock split. The total number of authorized shares of common stock and the par value per share of the Company's common stock did not change as a result of the reverse stock split. As a result of the reverse stock split, an amount equal to the decreased value of the common stock was reclassified from “common stock” to “additional paid-in capital.” In addition, the conversion prices of the outstanding convertible notes and certain series of preferred stock, as well as the exercise prices or number of shares issuable upon exercise of outstanding warrants, were adjusted to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. All fractional shares were rounded up.
Income Taxes
The Company applies ASC 740-10, Accounting for Income Taxes (“ASC 740-10”), which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax basis and operating loss, capital loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
7
Table of Contents
The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits as a component of general and administrative expenses. The Company’s federal tax return and any state tax returns are not currently under examination.
Revenue Recognition
The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 establishes a principle for recognizing revenue upon the transfer of promised goods or services to customers in an amount that reflects the expected consideration received in exchange for those goods or services. The core principle of ASC 606 is to recognize revenue to depict the transfer of promised goods or services to clients in an amount that reflects the consideration the entity expects to be entitled in exchange for those goods or services.
The Company derives revenue from business services associated with direct tele-physician provider patient fee services, telehealth services and institutional services provided to our clients.
The Company determines revenue recognition in accordance with ASC 606, through the following five steps:
1) Identify the contract with a customer
The Company considers the terms and conditions of its contracts and the Company’s customary business practices in identifying its contracts under ASC 606. The Company determines it has a contract with a customer when the contract has been approved by both parties, it can identify each party’s rights regarding the services to be transferred and the payment terms for the services, it has determined the customer to have the ability and intent to pay, and the contract has commercial substance. The Company applies judgment in determining the customer’s ability and intent to pay, which is based on a variety of factors, including the customer’s payment history or, in the case of a new customer, credit and financial information pertaining to the customer.
The Company also has service contracts with hospitals or hospital systems, physician practice groups, and other users. These customer contracts typically range from two to three years, with an automatic renewal process. The Company either invoices these customers for the monthly fixed fee in advance or at the end of the month, depending on the contract terms.
The contracts typically contain cancellation clauses with advance notice; therefore, the Company does not believe that it has any material outstanding commitment for future revenues beyond one year from the end of a reporting period.
2) Identify the performance obligations in the contract
Performance obligations promised in a contract are identified based on the services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the service either on its own or together with other resources that are readily available, and are distinct in the context of the contract, whereby the transfer of the services is separately identifiable from other promises in the contract. The Company’s contracts typically contain cancellation clauses with advance notice; therefore, the Company does not believe that they have any material outstanding commitments for future revenues beyond one year from the end of the reporting period.
3) Determine the transaction price
The total transaction price is based on the amount to which the Company is entitled to based on the contracts with its customers. The Company believes the quoted transaction prices in the customer contracts represent the stand-alone selling prices for each of the separate performance obligations which are distinct and priced separately within the contract. The transaction price for each service provided is independent and established in the contract and based on the duration of service provided or for a rate for service provided. Fees are established based on the service transferred to the client.
4) Allocate the transaction price to performance obligations in the contract
If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative stand-alone selling price (“SSP”). The determination of a SSP for each distinct performance obligation requires judgment. The Company believes the quoted transaction prices in the customer contracts represent the standalone selling prices for each of the separate performance obligations that are distinct and priced separately within the contract.
5) Recognize revenue when or as the Company satisfies a performance obligation
Revenue is recognized when or as control of the promised goods or service is transferred to the customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services.
Patient Fees Services and Performance Obligation
Patient Fee Services
Patient fees represent a series of distinct services because performance obligations are met when the Company’s physicians provide professional medical services to patients at the client site. The patient benefits from professional services when care is rendered by the Company’s medical professionals. Revenue recognition commences when the Company satisfies its performance obligation to provide professional medical services to patients.
The Company acts as the principal in these arrangements because it controls the medical services before they are transferred to the patient. This control is evidenced by the Company’s primary responsibility for fulfilling the service and its direct authority over the affiliated physicians, including the right to direct their clinical activities and administrative protocols.
8
Table of Contents
Patient Fee Contracts Involving Third-Party Payors
The Company receives payments from patients, third-party payors, and others for patient fee services. Third-party payors reimburse based on contracted rates or billed charges, which are generally lower than billed amounts. The Company determines the transaction price on patient fees based on standard charges for services provided, reduced by adjustments provided to third-party payors, and implicit price concessions provided to uninsured patients. The Company monitors its revenue and receivables from third-party payors and records an estimated contractual allowance to properly account for the differences between billed and collected amounts.
Revenue from third-party payors is presented net of an estimated provision for contractual adjustments. Patient revenues are net of service credits and service adjustments, and implicit price concessions. These adjustments and implicit price concessions represent the difference between the amount billed and the estimated consideration the Company expects to receive, based on historical collection experience, market conditions and other factors. Although the Company believes that its approach to estimates and judgments as described herein is reasonable, actual results could differ, from estimated amounts and such difference could be material.
All of the Company’s telemedicine contracts for patient reimbursement fees are directly billed to the payors by the Company. The Company earns patient fees by providing high acuity patient care solutions. For patient fees, performance obligations are met when the Company’s physicians provide professional medical services to patients at the client site as this is deemed as transfer of goods and services to respective patients. The patient benefits from the professional services when care is rendered by the Company’s medical professionals. The revenue is determined based on the telemedicine billing code(s) associated with the respective professional service rendered to patients.
The Company earns primarily from reimbursement from the following third-party payors:
Medicare
The Company’s affiliated provider network is reimbursed by the Medicare Part B and Part C programs for certain of the telemedicine services it provides to Medicare beneficiaries. Medicare coverage for telemedicine services is treated distinctly from other types of professional medical services and is limited by federal statute and subject to specific conditions of participation and payment pursuant to Medicare regulations, policies and guidelines, including the location of the patient, the type of service, and the modality for delivering the telemedicine service, among others.
Medicaid
Medicaid programs are funded jointly by the federal government and the states and are administered by states (or the state’s designated managed care or other similar organizations) under approved plans. Our affiliated provider network is reimbursed by certain State Medicaid programs for certain of the telemedicine services it provides to Medicaid beneficiaries. Medicaid coverage for telemedicine services varies by state and is subject to specific conditions of participation and payment.
Commercial Insurance Providers
The Company is reimbursed by commercial insurance carriers. The basis for payment to the commercial insurance providers is consistent with Medicare reimbursement fee structure guidelines and the Company is in-network or out-of-network with the commercial insurance carriers based on state and insurer requirements.
Telehealth Fees Service Contracts and Performance Obligation
Contract For Telemedicine Care Services
Performance obligations in the contract for telemedicine care are based on services provided via the use of hardware and software integration that includes multi-participant video conferencing, and electronic communication for 24 hours per day, seven days per week for the duration of the contract. The Company provides administrative support for the tele-physician services and coordinates the services of its clinicians’ network through administrative support, hardware support, and software support and provider coverage availability. The Company provides coverage availability of its physician services ranging from 12 to 24 hours per day. Performance obligations in the contract for these services transferred to the customer are distinct in the context of the contract, whereby the transfer of the services is separately identifiable from patient services and institutional services obligations. Performance obligations are met when the Company provides administrative, business, and medical records and reports related to their professional services rendered pursuant to the agreement in such format and upon such interval as hospitals may require. Revenue from telemedicine care services is included in telehealth fees in the condensed consolidated financial statements.
The Company recognizes revenue for variable consideration when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The Company estimates the amount of revenue to be recognized on variable consideration, using the expected value or the most likely amount method, whichever is expected to better predict the amount. The Company’s estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on assessments of legal enforceability, performance, and all information that is reasonably available to the Company. The determination of the amount of revenue the Company can recognize each accounting period requires management to make estimates and judgments on the estimated expected customer life or expected performance period.
The Company commences revenue recognition when the Company satisfies its performance obligation to provide the contractual tele-physician hours services. Prior to the commencement of services, customers generally make initial start-up nonrefundable payments to the Company when contracting for Company training, hardware and software installation and integration, which includes a onetime setup of software security, API interfaces, and compatibility between existing hospital equipment and hardware and software. The start-up fees do not significantly modify or customize the other goods in the contract. As the start-up service primarily covers initial administrative services for which the Company’s clients can cancel future services upon completion, management considers it to be separable from the ongoing business services, and the Company records start-up fees as revenue when the start-up service is completed over time, using the input method to measure progress each financial period.
9
Table of Contents
Institutional Fees Service Contracts and Performance Obligation
Contract For Electroencephalogram (“EEG”) Professional Interpretation Services
Performance obligations in the contract for EEG professional interpretation services are based on the number of professional services EEG interpretation the Company provides. The performance obligation in the contract for these services transferred to the customer is distinct in the context of the contract, whereby the transfer of the services is separately identifiable from other promises in the contract. To facilitate the delivery of the EEG professional interpretation services, the Company’s physicians use EEG telemedicine equipment provided by the Company. The performance obligation is satisfied based on the number of EEG professional interpretations performed by the Company’s physicians. The number of professional interpretations is traced monthly by both parties and used to determine the revenue earned based on established contractual rates and is included in institutional fees in the condensed consolidated financial statements.
Under
most of the Company’s contracts, including contracts with its
The Company commences revenue recognition on EEG professional interpretation services when the Company satisfies its performance obligation to provide professional interpretation monthly.
Disaggregation of revenue
The following table provides information about disaggregated revenue from continuing operations by timing of revenue recognition:
| For the three months ended | For the nine months ended | |||||||||||||||
| September 30, | September 30, | September 30, | September 30, | |||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Timing of revenue recognition | ||||||||||||||||
| Products and services transferred over time | $ | $ | $ | $ | ||||||||||||
| Products and services transferred at a point in time | ||||||||||||||||
| Total Revenue | $ | $ | $ | $ | ||||||||||||
Net Loss Per Common Share
The Company computes income (loss) per common share, in accordance with ASC Topic 260, Earnings Per Share, which requires dual presentation of basic and diluted earnings per share. Basic income or loss per common share is computed by dividing net income or loss by the weighted average number of common shares outstanding during the period. No potential diluted common shares are included in the computation of any diluted per share amount when a loss is reported. Diluted income or loss per common share is computed by dividing net income or loss by the weighted average number of common shares outstanding, adjusted for the effect of potentially dilutive securities, using the treasury stock method and the if-converted method, as applicable.
The following table presents basic and diluted earnings per share attributable to continuing operations for the three and nine months ended September 30, 2026, and 2025.
| For Three months ended | For the Nine Months Ended | |||||||||||||||
| September 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | |||||||||||||
| Net loss from continuing operations - basic and diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted average shares outstanding – basic and diluted | ||||||||||||||||
| Net loss per share from continuing operations – basic and diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Excluded securities: (1) * | ||||||||||||||||
| Public Warrants | ||||||||||||||||
| Private Warrants | ||||||||||||||||
| Bridge Warrants | ||||||||||||||||
| Extension Warrants | ||||||||||||||||
| September 2024 Warrants | ||||||||||||||||
| Quantum Convertible Note, related party (2) | ||||||||||||||||
| Exchange Note (2) | ||||||||||||||||
| September 2024 Convertible Note (3) | ||||||||||||||||
| Series A Preferred stock common stock equivalents (4) | ||||||||||||||||
| Stock options granted | ||||||||||||||||
| Common stock issuance obligation | ||||||||||||||||
| March 2025 Convertible Note (5) | ||||||||||||||||
| May 2025 Convertible Note (6) | ||||||||||||||||
| Common Stock Warrants | ||||||||||||||||
| ClearThink Convertible Note (7) | ||||||||||||||||
| Labrys Convertible Promissory Note (8) | - | - | ||||||||||||||
| * |
10
Table of Contents
| (1) | ||
| (2) |
| (3) | ||
| (4) | ||
| (5) | ||
| (6) | ||
| (7) | ||
| (8) | Includes the interest amount thereon and assumes the average closing price for the reporting period. |
The following table presents basic and diluted earnings (loss) per share attributable to discontinued operations for the three and nine months ended September 30, 2026, and 2025.
| For Three months ended | For the Nine Months Ended | |||||||||||||||
| September 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | |||||||||||||
| Net (loss) income from discontinued operations – basic and diluted | $ | $ | ( | ) | $ | $ | ( | ) | ||||||||
| Weighted average shares outstanding – basic and diluted | ||||||||||||||||
| Net (loss) income per share from discontinued operations – basic and diluted | $ | $ | ( | ) | $ | $ | ( | ) | ||||||||
| Excluded securities: (1) * | ||||||||||||||||
| Public Warrants | ||||||||||||||||
| Private Warrants | ||||||||||||||||
| Bridge Warrants | ||||||||||||||||
| Extension Warrants | ||||||||||||||||
| September 2024 Warrants | ||||||||||||||||
| Quantum Convertible Note, related party (2) | ||||||||||||||||
| Exchange Note (2) | ||||||||||||||||
| September 2024 Convertible Note (3) | ||||||||||||||||
| Series A Preferred stock common stock equivalents (4) | ||||||||||||||||
| Stock options granted | ||||||||||||||||
| Common stock issuance obligation | ||||||||||||||||
| March 2025 Convertible Note (5) | ||||||||||||||||
| May 2025 Convertible Note (6) | ||||||||||||||||
| Common Stock Warrants | ||||||||||||||||
| * |
| (1) | ||
| (2) | ||
| (3) | ||
| (4) | ||
| (5) | Includes
the interest amount thereon and assumes the floor conversion price of $ | |
| (6) |
Cash
The
Company considers all highly liquid investments with maturities of three months or less at the time of
acquisition to be cash equivalents. The Company had
Periodically,
the Company may carry cash balances at financial institutions more than the federally insured limit of
$
11
Table of Contents
Accounts Receivable and Credit losses
The Company carries its accounts receivable at net realizable value. The Company maintains an allowance for credit losses for the estimated losses resulting from the inability of the Company’s clients to pay their invoices. Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables.
As
of September 30, 2026, and December 31, 2025, respectively, the allowance for credit losses was
$
The following table presents the Company’s allowance for credit losses on September 30, 2026, and December 31, 2025:
| September 30, 2026 | December 31, 2025 | |||||||
| Beginning allowance for credit losses | $ | $ | ||||||
| Add: Credit loss expense | ||||||||
| Less: Accounts receivable write-off included in allowance for credit losses above | ( | ) | ( | ) | ||||
| Ending allowance for credit losses | $ | $ | ||||||
Leases
The Company accounts for leases under ASC 842, Leases. The Company determines whether an arrangement is or contains a lease at inception. Operating leases are recorded as right-of-use (ROU) assets, current operating lease liabilities, and non-current operating lease liabilities on the Company’s condensed consolidated balance sheets. Finance leases are included in fixed assets and finance lease liabilities on the Company’s condensed consolidated balance sheets. Operating and finance lease right-of-use assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease right-of-use asset, unless an implicit rate is readily determinable. As most of our leases do not provide an implicit rate, we generally use our incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. As we do not have any outstanding public debt, we estimated the incremental borrowing rate based on our estimated credit rating and available market information. The incremental borrowing rate is subsequently reassessed upon a modification to the lease agreement.
As permitted under ASC 842, the Company has made an accounting policy election not to apply the recognition provisions of ASC 842 to short-term leases (leases with a lease term of 12 months or less that do not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise); instead, the Company will recognize the lease payments for short-term leases on a straight-line basis over the lease term.
Stock-based Compensation
The Company accounts for stock-based compensation in accordance with ASC 718, Compensation-Stock Compensation. Under the fair value recognition provisions, stock-based compensation cost is measured at the grant date based on the fair value of the award. For employee awards, cost is recognized on a straight-line basis over the requisite service period. For nonemployee awards, cost is recognized in the same period and in the same manner as if the Company had paid cash for the services; fully vested, nonforfeitable shares granted to nonemployees are recognized when granted. The fair value of stock awards, including shares of common stock granted to employees and consultants, is based on the closing price of the Company's common stock on the grant date. The Company estimates the fair value of share options using the Black-Scholes option-pricing model, utilizing assumptions related to the contractual term of the instruments, estimated volatility of the price of the Common Stock, and current interest rates. The Company accounts for forfeitures as they occur.
Fair Value of Financial Instruments
“Fair value” is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. ASC 820 establishes a fair value hierarchy that prioritizes and ranks the level of observability of inputs used to measure investments at fair value. The observability of inputs is impacted by a number of factors, including the type of investment, characteristics specific to the investment, market conditions and other factors. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Investments with readily available quoted prices or for which fair value can be measured from quoted prices in active markets will typically have a higher degree of input observability and a lesser degree of judgment applied in determining fair value.
The carrying amounts are reflected in the accompanying balance sheets for cash, accounts receivable, due from/to related party, debt measured at amortized cost, accounts payable and accrued liabilities approximate fair value due to their short-term nature. The three levels of the fair value hierarchy under ASC 820 are as follows:
| ● | “Level 1”, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; | |
| ● | “Level 2”, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and | |
| ● | “Level 3”, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. |
12
Table of Contents
In some cases, the inputs used to measure fair value might fall within different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the investment is categorized in its entirety is determined based on the lowest level input that is significant to the investment. Assessing the significance of a particular input to the valuation of an investment in its entirety requires judgment and considers factors specific to the investment. The categorization of an investment within the hierarchy is based upon the pricing transparency of the investment and does not necessarily correspond to the perceived risk of that investment.
See Note 16 - Fair Value Measurements for additional information on assets and liabilities measured at fair value.
Derivative Financial Instruments
The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain
features that qualify as embedded derivatives in accordance with ASC 815, Derivatives and Hedging.
Derivative instruments are recorded at fair value on the grant date and re-valued at each reporting date, with
changes in the fair value reported in the consolidated statements of operations. Derivative assets and
liabilities are classified in the consolidated balance sheets as current or non-current based on whether or
not net cash settlement or conversion of the instrument could be required within
Warrant Instruments
The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity and ASC 815 (Derivatives and Hedging). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.
For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. The Company has determined that its Public warrants, Private warrants, Bridge warrants, September 2024 warrants, Pre-funded warrants, Common Stock warrants and Extension warrants are freestanding and meet equity classification under ASC 815 (Derivatives and Hedging) and are therefore classified in equity.
Long – term Investments
For equity investments that do not have readily determinable fair values, the Company measures the equity investment at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investments of the Company. The Company periodically evaluates the carrying value of the equity investment, or when events and circumstances indicate that the carrying amount of an asset may not be recovered. On a quarterly basis, the Company reviews their equity investments without readily determinable fair values for impairment and considers several qualitative factors such as whether there is a significant deterioration in earnings performance, credit rating, asset quality, or business prospects of the investee in determining if impairment exists. If the investment is considered impaired, an impairment loss equal to the amount by which the carrying value exceeds its fair value is recorded through a charge to earnings. The impairment loss may be reversed in a subsequent period if there are observable transactions for the identical or similar investment of the same issuer at a higher amount than the carrying amount that was established when the impairment was recognized.
On
January 16, 2026, the Company entered into a Stock Purchase Agreement with GoMyRx, Inc., a Wyoming corporation
(“GoMyRx”), and Go Biz Holdings, LLC, a Wyoming limited liability company (“GBiz”),
pursuant to which the Company agreed to acquire an approximately
As
of the reporting date, the Company has funded $
The Company does not have the ability to exercise significant influence over GoMyRx and, accordingly, this investment is not accounted for under the equity method. The investment is accounted for as an equity investment in a private company, measured at cost, less impairment, with adjustments for observable price changes, if any.
Fixed Assets
Fixed
assets are recorded at historical cost, less accumulated depreciation. The Company expenses fixed assets
purchased that are less than $
| Estimated Useful Life | ||
| Office equipment | ||
| Medical equipment | ||
| Furniture | ||
| Leased equipment | ||
| Leasehold improvements |
13
Table of Contents
Goodwill
Goodwill represents the excess of purchase price in a business combination over the fair value of the net identifiable assets acquired. We evaluate goodwill for impairment at the reporting unit level by assessing whether it is more likely than not that the fair value of a reporting unit exceeds it carrying value. If this assessment concludes that it is more likely than not that the fair value of a reporting unit exceeds its carrying value, then goodwill is not considered impaired and no further impairment testing is required. Conversely, if the assessment concludes that it is more likely than not that the fair value of a reporting unit is less than it carrying value, a goodwill impairment test is performed to compare the fair value of the reporting unit to its carrying value. The Company determines fair value of the reporting unit using both income and market-based models. Our models contain significant assumptions and accounting estimates about discount rates, future cash flows, and terminal values that could materially affect our operating results or financial position if they were to change significantly in the future and could result in an impairment. We perform our goodwill impairment assessment whenever events or changes in facts or circumstances indicate that impairment may exist and during the fourth quarter each year. The cash flow estimates and discount rates incorporate management’s best estimates, using appropriate and customary assumptions and projections at the date of evaluation. For the three and nine months ended September 30, 2026, the Company performed qualitative analysis by assessing that no adverse economic, industry, operational, or regulatory indicators were identified that would suggest impairment. Based on the qualitative assessment of relevant factors, the Company concludes that no impairment indicators or triggering events were identified that required the Company to perform a quantitative analysis.
Intangible Assets
Intangible
assets are presented at their historical costs, net of amortization. Historical cost of intangible assets
acquired in a business combination represents the fair value at acquisition. The fair value at acquisition is
determined based on the appraised value of the asset. Intangible assets are comprised of developed technology
and customer relationships.
| Estimated | September 30, | December 31, | ||||||||
| Useful Life | 2026 | 2025 | ||||||||
| Customer relationships | ||||||||||
| Developed technology | ||||||||||
| Accumulated amortization | ( | ) | ( | ) | ||||||
| Intangible assets, net | $ | $ | ||||||||
Expected amortization expense is as follows:
| Year ending December 31, 2026 (remaining 3 months) | ||||
| Year ending December 31, 2027 | ||||
| Year ending December 31, 2028 | ||||
| Year ending December 31, 2029 | ||||
| Year ending December 31, 2030 | ||||
| Thereafter | ||||
| Total | $ |
For
the three months ended September 30, 2026, and September 30, 2025, the Company recorded amortization expense
of $
Impairment of Long-lived and Intangible Assets Other than Goodwill
In accordance with ASC 360-10, the Company, on a regular basis, reviews the carrying amount of long-lived assets, including fixed assets, right-of-use assets and intangible assets, for the existence of facts or circumstances, both internally and externally, that suggest impairment. The Company determines if the carrying amount of a long-lived asset is impaired based on anticipated undiscounted cash flows, before interest, from the use of the asset. In the event of impairment, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the asset. Fair value is determined based on the appraised value of the assets or the anticipated cash flows from the use of the asset, discounted at a rate commensurate with the risk involved.
Original Issue Discount on Debt
When the Company issues notes payable with a face value higher than the proceeds it receives, it records the difference as a debt discount and amortizes the discount as interest expense over the life of the underlying note payable.
Loss Contingencies and Litigation
The Company records reserve for loss contingencies if (a) information available prior to issuance of the condensed consolidated financial statements indicates that it is probable that an asset had been impaired or a liability had been incurred at the date of the condensed consolidated financial statements and (b) the amount of loss can be reasonably estimated. If one or both criteria for accrual are not met, but there is at least a reasonable possibility that a material loss will occur, the Company does not record and reserve for a loss contingency but describes the contingency within a note and provides detail, when possible, of the estimated potential loss or range of loss. If an estimate cannot be made, a statement to that effect is made.
Recent Accounting Pronouncements
Recent Accounting Standards Adopted by the Company
ASU 2024-04: In November 2024, the FASB issued ASU 2024-04, Debt—Debt with Conversion and Other Options (Subtopic 470-20)—Induced Conversions of Convertible Debt Instruments. The ASU clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. The standard is effective for annual periods beginning after December 15, 2025, and interim periods within those annual periods, with early adoption permitted for all entities that have adopted the amendments in ASU 2020-06. We adopted this standard during the first quarter of 2026 on a prospective basis. The adoption did not have a material impact on the Company’s condensed consolidated financial statements presented.
14
Table of Contents
ASU 2025-05: In July 2025, the FASB issued ASU 2025-05, Financial Instruments—Credit Losses (Topic 326): Measurements of Credit Losses for Accounts Receivable and Contract Assets (ASU 2025-05). The amendments in this update provide a practical expedient related to the estimation of expected credit losses for current accounts receivable and current contract assets that arise from transactions accounted for under ASC 606. Under ASU 2025-05, an entity is required to disclose whether it has elected to use the practical expedient. An entity that makes the accounting policy election is required to disclose the date through which subsequent cash collections are evaluated. The standard is effective for annual periods beginning after December 15, 2025, and interim periods within those annual periods, with early adoption permitted. The Company adopted this standard during the first quarter of 2026 on a prospective basis and did not elect the practical expedient. The adoption did not have a material impact on the Company’s condensed consolidated financial statements presented.
Accounting Pronouncements Not Yet Effective
ASU 2024-03: In November 2024, the FASB issued ASU No. 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), which requires disaggregated disclosure of income statement expenses for public business entities. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of ASU 2024-03 on its disclosures in the condensed consolidated financial statements.
ASU 2025-03: In May 2025, the FASB issued Accounting Standards Update No. 2025-03, Business Combinations (Topic 805), and Consolidation (Topic 810): Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity (“ASU 2025-03”). ASU 2025-03 changes how companies determine the accounting acquirer in certain business combinations involving variable interest entities. The new guidance requires considering the factors used for other acquisition transactions to assess which party is the accounting acquirer. ASU 2025-03 is effective for the Company’s annual reporting periods beginning on January 1, 2027. Early adoption is permitted. The Company is currently evaluating the impact of adopting this new accounting guidance on its condensed financial statements and related disclosures.
ASU 2025-04: In May 2025, the FASB issued Accounting Standards Update No. 2025-04, Compensation – Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Clarifications to Share-Based Consideration Payable to a Customer (“ASU 2025-04”). ASU 2025-04 revises the definition of a performance condition, eliminates the forfeiture policy election for service conditions, and clarifies that the variable consideration constraint in Topic 606 does not apply to share-based consideration payable to customers. The new guidance requires entities to consistently account for share-based awards granted to customers by clarifying the treatment of vesting conditions and ensuring alignment with Topic 606 and Topic 718. ASU 2025-04 is effective for fiscal years beginning after December 15, 2026, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting this new accounting guidance on its condensed financial statements and related disclosures.
ASU 2025-06: In September 2025, the FASB issued ASU 2025-06- Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software (ASU 2025-06), which is intended to simplify the capitalization guidance for internal-use software by removing references to project stages and clarifying when the capitalizing of eligible costs is required. ASU 2025-06 is effective for annual periods beginning after December 15, 2027, and interim periods within those fiscal years. Early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on its disclosures in the condensed consolidated financial statements.
ASU 2025-11: In December 2025, the FASB issued ASU No. 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements, which clarifies the guidance in Topic 270 to improve the consistency of interim financial reporting. The ASU provides a comprehensive list of required interim disclosures and introduces a disclosure principle requiring entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. ASU 2025-11 is effective for fiscal years beginning after December 15, 2027, including interim periods within those fiscal years, with early adoption permitted. The Company is in the process of evaluating the impact of this new guidance on its disclosures in the condensed consolidated financial statements.
ASU 2025-12: In December 2025, the FASB issued ASU No. 2025-12, Codification Improvements. The ASU addresses thirty-three items, representing the changes to the Codification that (1) clarify, (2) correct errors, or (3) make minor improvements. Generally, the amendments in this Update are not intended to result in significant changes for most entities. The ASU is effective for interim reporting periods within annual reporting periods beginning after December 15, 2026. The adoption method of this ASU may vary, on an issue-by-issue basis. Early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on its disclosures in the condensed consolidated financial statements.
Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s condensed consolidated financial statements.
The Company continues to evaluate the impact of new accounting pronouncements, including enhanced disclosure requirements, on its business processes, controls and systems.
Note 3 Discontinued Operations
On
May 31, 2026, the Company entered into and consummated a Stock Purchase Agreement with Milton Chen, the
Company's then co-Chief Executive Officer, Chairman of the Board, and Chief Executive Officer of VSee Lab,
pursuant to which the Company sold all of its equity interests in VSee Lab, to Milton Chen. The divestiture
was part of a strategic decision to focus the Company's operations and resources on the physician services
business conducted through iDoc. As consideration for the transaction and the mutual release of certain
liabilities under the agreement, Milton Chen transferred to the Company
The
Company accounted for the
15
Table of Contents
No assets or liabilities were classified as held for sale as of September 30, 2026, as the sale of VSee Lab was completed on May 31, 2026. The revenues and expenses of VSee Lab have been separately presented as discontinued operations in the accompanying condensed consolidated financial statements.
The following table represents the major components of assets and liabilities from discontinued operations as of December 31, 2025:
| Balance sheet - Discontinued operations | December 31, 2025 | |||
| ASSETS | ||||
| Current assets: | ||||
| Cash | $ | |||
| Accounts receivable, net of allowance for credit losses of $ | ||||
| Prepaids and other current assets | ||||
| Current assets from discontinued operations | ||||
| Non-current assets: | ||||
| Fixed assets, net | ||||
| Non-current assets from discontinued operations | ||||
| Total assets from discontinued operations | $ | |||
| LIABILITIES | ||||
| Accounts payable and accrued liabilities | $ | |||
| Deferred revenue | ||||
| Loan payable, related party | ||||
| Total liabilities from discontinued operations | $ | |||
The following table represents the major components of the results of discontinued operations for the three and nine months ended September 30, 2026, and 2025:
| For the Three Months Ended | For the Nine Months Ended | |||||||||||||||
| Discontinued operations - net income (loss) | September 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | ||||||||||||
| Revenue | ||||||||||||||||
| Subscription fees | $ | $ | $ | $ | ||||||||||||
| Professional services and other fees | ||||||||||||||||
| Technical engineering fees | ||||||||||||||||
| Total revenue from discontinued operations | $ | $ | $ | $ | ||||||||||||
| Expenses: | ||||||||||||||||
| Cost of revenues | ||||||||||||||||
| Compensation and related benefits | ||||||||||||||||
| General and administrative | ||||||||||||||||
| Interest expense | ||||||||||||||||
| Other income (expense), net | ( | ) | ||||||||||||||
| Gain on sale of discontinuing operations | ( | ) | ||||||||||||||
| (Loss) income from discontinued before provision for income taxes | ( | ) | ( | ) | ||||||||||||
| Provision for income taxes | ( | ) | ( | ) | ||||||||||||
| Net (loss) income from discontinued operations | $ | $ | ( | ) | $ | $ | ( | ) | ||||||||
Note 4 Leases
Operating Leases
The Company has an operating lease for real estate. Operating lease right-of-use assets are summarized below.
| September 30, 2026 | December 31, 2025 | |||||||
| Office lease | $ | $ | ||||||
| Less: Accumulated amortization | ( | ) | ( | ) | ||||
| Right-of-use assets, net | $ | $ | ||||||
16
Table of Contents
Operating lease liabilities are summarized below:
| September 30, 2026 | December 31, 2025 | |||||||
| Office lease | $ | $ | ||||||
| Less: current portion | ( | ) | ( | ) | ||||
| Long term portion | $ | $ | ||||||
Future minimum rent payments under the operating lease are as follows:
| Total | ||||
| Year ending December 31, 2026 (remaining 3 months) | ||||
| Year ending December 31, 2027 | ||||
| Total future minimum lease payments | ||||
| Less: Imputed interest | ( | ) | ||
| Present value of payments | $ | |||
Expenses incurred with respect to the Company’s operating leases during the three and nine months ended September 30, 2026, which are included in general and administrative expenses on the condensed consolidated statements of operations are set forth below.
| For the Three Months Ended | ||||||||
| September 30, 2026 | September 30, 2025 | |||||||
| Operating lease expense | $ | $ | ||||||
| Total operating lease expense | $ | $ | ||||||
| For the Nine Months Ended | ||||||||
| September 30, 2026 | September 30, 2025 | |||||||
| Operating lease expense | $ | $ | ||||||
| Total operating lease expense | $ | $ | ||||||
The weighted average remaining lease term and the weighted average discount rate on the operating leases are set forth below.
| September 30, 2026 | December 31, 2025 | |||||||
| Weighted average remaining lease term (years) | ||||||||
| Weighted average discount rate | % | % | ||||||
Finance Leases
Pursuant
to a settlement agreement, the Company paid $
Accordingly, the finance lease liabilities have been fully settled as of September 30, 2026.
| September
30, 2026 | December 31, 2025 | ||||||||
| Equipment lease | $ | $ | |||||||
| Less: Accumulated amortization | ( | ) | ( | ) | |||||
| Leased equipment, net | $ | $ | |||||||
Finance lease liabilities are summarized below:
| September
30, 2026 | December 31, 2025 | |||||||
| Equipment lease | $ | $ | ||||||
| Less: current portion | ( | ) | ||||||
| Long-term portion | $ | $ | ||||||
Total
finance lease cash payments made during the three and nine months ended September 30, 2026, were $
Expenses incurred with respect to the Company’s finance leases during the three and nine months ended September 30, 2026, and September 30, 2025, which are included in the condensed consolidated statements of operations are set forth below.
| For the Three Months Ended | ||||||||
| September 30, 2026 | September 30, 2025 | |||||||
| Amortization expense | $ | $ | ||||||
| Interest expense | ||||||||
| Total finance lease expense | $ | $ | ||||||
17
Table of Contents
| For the Nine Months Ended | ||||||||
| September 30, 2026 | September 30, 2025 | |||||||
| Amortization expense | $ | $ | ||||||
| Interest expense | ||||||||
| Total finance lease expense | $ | $ | ||||||
The weighted average remaining lease term and the weighted average discount rate on the finance leases are set forth below.
| September 30, 2026 | December 31, 2025 | |||||||
| Weighted average remaining lease term (years)* | - | |||||||
| Weighted average discount rate* | % | % | ||||||
| * |
Note 5 Accounts Payable and Accrued Liabilities
The components of accounts payable and accrued liabilities are summarized as follows:
| September 30, 2026 | December 31, 2025 | |||||||
| Accounts payable | $ | $ | ||||||
| Accrued compensation and benefits | ||||||||
| Accrued interest | ||||||||
| Accrued financing lease | ||||||||
| Other accrued liabilities | ||||||||
| $ | $ | |||||||
Silverback Capital Settlement Agreement
On October 14, 2026, the Company entered into a Settlement Agreement and Stipulation with Silverback Capital Corporation (“SCC”)
to settle bona fide outstanding liabilities and obligations acquired by SCC from certain of the Company’s creditors. Pursuant
to the agreement, claims with an aggregate claim amount of approximately $
Under the terms of the settlement agreement, settlement shares are issuable from time to time upon request by SCC and are priced based
on the Closing Price of the Company’s common stock immediately preceding the settlement date. If the market price declines below
the Closing Price, the purchase price is adjusted to the lower of (i) the Closing Price or (ii)
Following court approval on August 5, 2026, approving the Settlement Agreement pursuant to Section 3(a)(10) of the Securities Act,
the Company commenced settlement of the claims through the issuance of common stock to Silverback Capital Corporation in accordance
with the terms of the agreement. During the three months ended September 30, 2026, the Company issued
Note 6 Factoring Payable
iDoc
previously entered into three Future Receipts Sale Agreements (dated June 21, 2023, June 28, 2023, and October
13, 2023), under which it sold future receipts of $
Note 7 Line of Credit and Notes Payable, net of discount
The following is a summary of the notes payable as of September 30, 2026, and December 31, 2025:
| Notes Payable | September 30,
2026 | December 31, 2025 | |||||||
| Note payable issued November 29, 2021 | $ | $ | |||||||
| Note payable issued December 1, 2021 | |||||||||
| Note payable issued August 18, 2023 | |||||||||
| Note payable issued August 3, 2023 | |||||||||
| September 2025 Promissory Note | |||||||||
| Encompass SBA loan | |||||||||
| First Insurance Funding loan | |||||||||
| Total notes payable | |||||||||
| Less: Current portion | ( | ) | ( | ) | |||||
| Less: Fair value adjustment for debt | ( | ) | ( | ) | |||||
| Total notes payable, net of current portion | $ | $ | |||||||
Required principal payments under the Company’s notes payable are as follows:
| Year Ending December 31, 2026 (Remaining 3 months) | $ | |||
| Year Ending December 31, 2027 | ||||
| Year Ending December 31, 2028 | ||||
| Year ending December 31, 2029 | ||||
| Year ending December 31, 2030 | ||||
| Thereafter | ||||
| Total | $ |
18
Table of Contents
Description of Notes Payable
As a result of the acquisition of iDoc and at the closing of the Business Combination on June 24, 2024, the Company assumed the following outstanding notes payable liabilities from iDoc.
| (1) | On
November 29, 2021, iDoc issued a $ | |
| (2) | On
December 1, 2021, iDoc issued a promissory note to a bank in the amount of $ | |
| (3) | On
August 3, 2023, iDoc issued a | |
| (4) | On
August 18, 2023, iDoc issued an |
March 2025 Promissory Note
On
March 20, 2025, the Company issued a senior secured convertible promissory note in the principal amount of
$
On
November 11, 2025, the outstanding principal and accrued interest, totaling $
September 2025 Promissory Note
On
September 5, 2025, the Company entered into a Master Business Loan Agreement (the “MBLA”) whereby
the investor agreed to, for a period of up to three years, make advances to the Company (each, an
“Advance”) in the aggregate amount of $
19
Table of Contents
On
September 5, 2025, the investor made an initial Advance of $
The
September 2025 Promissory Note may be prepaid at any time by payment of an amount equal to the Initial Advance
plus
The
note was repaid during the quarter ended September 30, 2026. As of September 30, 2026, and December 31, 2025,
the outstanding balance on the September 2025 Promissory Note is $
October Promissory Note - 1
On
October 9, 2025, the Company entered into a note purchase agreement (the “October Promissory Note - 1
Purchase Agreement”) with an accredited institutional investor (the “October Promissory Note - 1
Investor”) pursuant to which the Company issued to the October Promissory Note - 1 Investor a secured
note in the aggregate principal amount of $
On
December 10, 2025, the October Promissory Note - 1 was entirely paid off by the Company. The interest expense
recognized on the October Promissory Note - 1 for the three and nine months ended September 30, 2025, was
$
October Promissory Note - 2
On
October 20, 2025, the Company entered into a note purchase agreement (the “October Promissory Note - 2
Purchase Agreement”) with an accredited institutional investor (the “October Promissory Note - 2
Investor”) pursuant to which the Company issued to the October Promissory Note - 2 Investor a secured
note in the aggregate principal amount of $
On
December 10, 2025, the October Promissory Note - 2 was entirely paid off by the Company. The interest expense
recognized on the October Promissory Note - 2 for the three and nine months ended September 30, 2025, was
$
First Insurance Funding Agreement
The Company entered into a Premium Finance Agreement, effective January 1, 2026, with First Insurance Funding (“First Insurance”), to finance insurance premiums related to a management liability insurance policy.
Under
the agreement, First Insurance financed insurance premiums and related taxes and fees totaling approximately
$
The
Company made a down payment of $
If
any payment due under the Premium Finance Agreement is not paid when due, a late charge will be assessed on
any installment at least 5 days in default, and the late charge will equal
20
Table of Contents
As
of September 30, 2026, and December 31, 2025, the Company had an outstanding balance of $
Line of credit
On November 29, 2021, iDoc received a revolving line of credit from a bank as described in the above “Description of Notes Payable” section. The line of credit is collateralized by iDoc’s assets.
On
January 15, 2026, the Company entered into a settlement agreement with bank related to its outstanding loan
obligations. Pursuant to a settlement agreement, the Company paid $
The
Company recorded $
Encompass SBA Loan
As
part of the settlement agreement entered on February 16, 2026, to fully settle the Encompass Purchase
liability (see Note 11 – Commitments, Contingencies, and Concentration Risk), the Company was assigned
an SBA Economic Injury Disaster Loan with a principal balance of $
As
on September 30, 2026, the outstanding balance of the Encompass SBA Loan is $
Note 8 Convertible notes
March 2025 Convertible Note
On
March 20, 2025, the Company entered into a Convertible Note Purchase Agreement (the “March 2025
SPA”), pursuant to which the Company issued and sold a senior secured convertible promissory note in the
principal amount of $
The
March 2025 Convertible Note is convertible into shares of the Company’s common stock at any time after
three months from issuance (or earlier upon prepayment) by the holder, at a conversion price equal to the
greater of (i) $
The
March 2025 Convertible Note is prepayable at any time (unless an event of default has occurred) at
The March 2025 Convertible Note is secured by substantially all the Company’s assets and includes certain covenants which restrict the Company’s ability to incur additional indebtedness, grant liens, pay dividends, or dispose of assets without the lender’s consent.
In
connection with the March 2025 SPA and March 2025 Convertible Note, the Company also issued
21
Table of Contents
After
analyzing the terms of the March 2025 Convertible Note and its embedded features, the Company elected to
account for the March 2025 Convertible Note at fair value under the allowable fair value option election. As
such, the Company initially recognized the March 2025 Convertible Note at its fair value of $
On
October 21, 2025, the March 2025 Convertible Note consisting of principal amount of $
Following this transaction, the March 2025 Convertible Note was fully settled, and no principal remained outstanding as of September 30, 2026, and December 31, 2025.
The
interest expense recognized on the March 2025 Convertible Note for the three and nine months ended September
30, 2025, was $
April 2025 Promissory Note
On
April 15, 2025, the Company issued an unsecured promissory note to an institutional investor (the
“April 2025 Promissory Note”), with a principal balance of $
Upon
an event of default, the interest rate increases to the greater of
On
May 30, 2025, the Company issued a convertible promissory note (“May 2025 Convertible Note”) with
a principal amount of $
The
May 2025 Convertible Note states that the amount due and owing under the original April 2025 Promissory Note
is consolidated with the new May 2025 Convertible Note under the terms and conditions set forth therein; and
hence, this consolidation leads to a modification of the original debt arrangement. The modification involved
changes to the terms and cash flows of the debt. The present value of the cash flows under the new May 2025
Convertible Note differed by more than
In accordance with ASC 470-50, the original April 2025 Promissory Note was derecognized, and the new May 2025 Convertible Note was recognized at its fair value. Any gain or loss resulting from the extinguishment was recognized in earnings for the period.
The
Company recognized the May 2025 Convertible Note at fair value at $
May 2025 Convertible Note
On
May 30, 2025, the Company issued the May 2025 Convertible Note, which is one of a series of duly authorized
and validly issued promissory notes of the Company, issued and sold by the Company pursuant to the September
2024 Securities Purchase Agreement, dated as of March 31, 2025. The principal amount of the May 2025
Convertible Note is $
The May 2025 Convertible Note is convertible into shares of the Company’s common stock at any time while outstanding, at a conversion price equal to the lowest trading price of the Company’s common stock at any time after the original issue date.
The May 2025 Convertible Note is prepayable at any time (unless an event of default has occurred) with advance notice and is mandatorily prepayable upon the occurrence of a subsequent offering, with the redemption amount paid from the financing proceeds. Before any prepayment can be made, the holder has the option to convert the May 2025 Convertible Note into common stock at a conversion price equal to the lowest Trading Price (as defined in the May 2025 Convertible Note) of a share of the Company’s common stock at any time after the Original Issue Date, with respect to the prepayment amount. The May 2025 Convertible Note can be accelerated upon an event of default either automatically or at the option of the Holder, depending on the nature of the event. Upon an uncured event of default, the Holder may accelerate the note and require immediate payment of all outstanding principal and accrued interest.
If
any payment due under the May 2025 Convertible Note is not paid when due, the Company shall pay a late fee
equal to ten percent (
22
Table of Contents
The
Company elected to account for the May 2025 Convertible Note at fair value under the allowable fair value
option election. As such, the Company initially recognized the May 2025 Convertible Note at its fair value of
$
On
September 3, 2025, the May 2025 Convertible Note was amended, and the principal amount was increased by
$
On
February 23, 2026, the May 2025 Convertible Note having a fair value of $
Following this transaction, the May 2025 Convertible Note was fully settled, and no principal remained outstanding as of September 30, 2026.
The
interest expense recognized on the May 2025 Convertible Note for the three and nine months ended September 30,
2026, and 2025 was $
October 2025 Convertible Note
On
October 29, 2025, the Company entered into a convertible note purchase agreement (the “October 2025
Convertible Note Agreement”) with an accredited institutional investor (the “October 2025
Convertible Note Investor”), whereby the October 2025 Convertible Note Investor purchased a
convertible promissory note in the initial principal amount of $
On
December 18, 2025, the Company made a payment of $
Exchange Note
In
connection with a securities purchase agreement by and among DHAC, VSee Lab, iDoc and an investor (the
“Bridge Investor”) dated October 5, 2022 (the “Original Bridge SPA”), DHAC, VSee Lab,
and iDoc each issued to the Bridge Investor a
The
Exchange Note bears interest at a rate of
23
Table of Contents
The
monetary amount of the obligation is a fixed monetary amount known at inception as represented by the
Amortization of Principal Schedule in the Exchange Note (each, an “Amortization Payment”). As
a result, the Exchange Note represents a debt instrument that the Company must or may settle by issuing a
variable number of its equity shares as each Amortization Payment shall, at the option of the Company, be made
in whole or in part, in immediately available Dollars equal to the sum of the Amortization Payments provided
for in the Exchange Note or, subject to the Company complying with the equity conditions provided for in the
Exchange Note on the date of such Amortization Payment, in common stock issued at
The Exchange Note represents share-settled debt that requires or may require the Company to settle the debt instrument by delivering a variable number of shares with a then-current fair value equal to the principal amount of the note plus accrued and unpaid interest. As a result, the Exchange Note is required to be accounted for as a liability under ASC 480. As required under ASC 480, the liability will be re-measured at fair value at each reporting period with the changes in the fair value of the liability recognized in earnings.
On
August 8, 2024, $
On
November 26, 2024, $
On
September 3, 2025, $
In
October 2025, $
Following this transaction, the Exchange Note was fully settled, and no principal remained outstanding as of September 30, 2026, and December 31, 2025.
The
Company recognized an interest expense of $
Quantum Financing Purchase Agreement
On
November 21, 2023, DHAC entered into a convertible note purchase agreement (the “Quantum Purchase
Agreement”), pursuant to which an institutional and accredited investor (the “Quantum
Investor”) subscribed for and purchased, and DHAC would issue and sell to the Quantum Investor, at the
closing of the Business Combination, a
The
Quantum Convertible Note was issued and sold to the Quantum Investor subsequent to the closing of the Business
Combination on June 25, 2024. The Quantum Convertible Note was further amended on July 3, 2024, whereby the
maturity date of the Quantum Convertible Note was changed from June 25, 2025, to June 30, 2026, and that
On
June 25, 2024, $
On
July 3, 2024, the Company and the Quantum Investor agreed to modify certain terms of the Quantum Convertible
Note. The modifications included the extension of the maturity date from June 25, 2025, to June 30, 2026, and
an interest guarantee whereby the Quantum Investor would receive
24
Table of Contents
On
April 4, 2025, the Company issued
On
August 28, 2025, the Company agreed to issue
On
August 28, 2025, the Company and the Quantum Investor agreed to modify certain terms of the Quantum
Convertible Note. The modifications included the increase in the aggregate principal amount of the note from
$
In
October 2025, the Quantum Convertible Note consisting of $
In
May 2026, the Quantum Convertible Note consisting of $
As
of September 30, 2026, and December 31, 2025, the Quantum Convertible Note’s fair value was $
September 2024 Security Purchase Agreement
On
September 30, 2024, the Company entered into a securities purchase agreement (the “September 2024
SPA”) with an accredited and institutional investor, pursuant to which the Company issued and sold to
the investor promissory notes for an aggregate principal amount of $
The
September 2024 Convertible Note is convertible into shares of the Company’s common stock at any time at
an initial fixed conversion price of $
The September 2024 Convertible Note is secured by substantially all of the Company’s assets and includes certain covenants which restrict the Company’s ability to enter into certain agreements or transactions without the lender’s consent.
In
connection with the September 2024 SPA and September 2024 Convertible Note, the Company also issued a warrant
to the investor to purchase up to
After
analyzing the terms of the September 2024 Convertible Note and its embedded features, the Company elected to
account for the September 2024 Convertible Note at fair value under the allowable fair value option election.
As such, the Company initially recognized the September 2024 Convertible Note at its fair value and will
subsequently measure the note at fair value with changes in fair value recorded in current period earnings (or
other comprehensive income, if specific to Company credit risk). The Company initially recorded the September
2024 Convertible Note at its estimated issuance date fair value of $
In
October 2025, outstanding principal of $
25
Table of Contents
Following
this transaction, the September 2024 Convertible Note was fully settled, and no principal remained outstanding
as of December 31, 2025. The Company accounted for the conversion as a change in fair value of
$
The
Company recognized interest expense of $
ADI Funding Convertible Note
On
June 8, 2026, the Company entered into a Securities Purchase Agreement with ADI Funding, LLC (“ADI
Funding”), pursuant to which the Company issued a secured promissory note with an aggregate principal
amount of $
The
outstanding balance under the ADI Funding Convertible Note is due on November 30, 2026, unless earlier
prepaid, accelerated upon an event of default, or converted in accordance with its terms. The Company may
voluntarily prepay all or any portion of the outstanding balance at any time, provided that no event of
default exists, at a redemption price equal to
Upon
the occurrence and continuation of an event of default, the interest rate automatically increases to the
lesser of
After
evaluating the terms of the ADI Funding Convertible Note, including its conversion, redemption and default
provisions, the Company elected the fair value option pursuant to ASC 825, Financial Instruments. Accordingly,
the ADI Funding Convertible Note was initially recorded at fair value and will be subsequently remeasured at
fair value at each reporting date, with changes in fair value recognized in the condensed consolidated
statements of operations. The Company initially recorded the ADI Funding Convertible Note at its estimated
issuance date fair value of $
On June 12, 2026, the Company received a notice from ADI Funding alleging that an event of default had occurred under the ADI Funding Convertible Note and related transaction documents. On July 21, 2026, thereafter, the Company entered into a Settlement Agreement and Mutual Release (the "Settlement Agreement") with ADI Funding and M2B Funding Corp. ("M2B"). The Settlement Agreement was entered into to resolve all disputes among the parties arising from the alleged default and to establish revised settlement and repayment terms related to the outstanding indebtedness owed to ADI Funding.
Pursuant
to the Settlement Agreement, the Company agreed to repay the ADI Funding Convertible Note, including accrued
interest and other amounts due thereunder, on the earlier of (i) ninety (90) days following execution of the
Settlement Agreement or (ii) immediately upon receiving proceeds from certain financing transactions. In
addition, until the ADI Funding Convertible Note is repaid in full, the Company is required to apply fifty
percent (
As
additional consideration under the Settlement Agreement, the Company agreed to (i) pay ADI Funding $
The
Company evaluated the revised rights and obligations arising from the Settlement Agreement and concluded that
the transaction should be accounted for as an extinguishment of the ADI Funding Convertible Note. As part of
the extinguishment, the existing note was replaced with a revised debt arrangement consisting of the modified
ADI Funding Convertible Note, the ADI Promissory Note of $
Upon
settlement of the original ADI Funding Convertible Note on July 21, 2026, the Company determined the fair
value of the modified ADI Funding Convertible Note based on its original contractual terms and recorded the
note at an initial fair value of approximately $
26
Table of Contents
As
of September 30, 2026, and December 31, 2025, the ADI Funding Convertible Note’s fair value was $
ClearThink Convertible Note
On
June 22, 2026, the Company entered into a Securities Purchase Agreement with ClearThink Capital Partners, LLC
(“ClearThink”), pursuant to which the Company issued an unsecured promissory note with a principal
amount of $
The
ClearThink Convertible Note is convertible, at the Holder's option, into shares of the Company's common stock
beginning 180 days after issuance. The conversion price is equal to
Upon
the occurrence and continuation of an event of default, including non-payment, breaches of covenants,
bankruptcy-related events, delisting of the Company's common stock, or failure to comply with Exchange Act
reporting obligations, the outstanding amount becomes immediately due and payable. Upon an event of default,
ClearThink is entitled to receive a default amount equal to
After
evaluating the terms of the ClearThink Convertible Note, the Company elected the fair value option pursuant to
ASC 825, Financial Instruments. Accordingly, the ClearThink Convertible Note was initially recorded at
fair value and will subsequently be remeasured at fair value at each reporting date, with changes in fair
value recognized in the condensed consolidated statements of operations. The Company initially recorded the
ClearThink Convertible Note at its issuance date fair value of $
As
of September 30, 2026, and December 31, 2025, the ClearThink Convertible Note’s fair value was $
Vanquish Funding Convertible Note
On
June 18, 2026, the Company entered into a bridge note financing arrangement with Vanquish Funding Group Inc.
(“Vanquish Funding”), pursuant to which the Company issued a bridge promissory note with an
aggregate principal amount of $
Outstanding
principal and interest under the Vanquish Funding
The
Vanquish Funding Convertible Note may be prepaid by the Company at any time, subject to payment of a specified
percentage of the then-outstanding balance. The applicable prepayment percentage ranges from
Upon
the occurrence of an event of default, the outstanding principal and interest balance of the Vanquish Funding
Convertible Note is increased to
As
of September 30, 2026, and December 31, 2025, the Vanquish Funding Convertible Note’s carrying value was
$
Vanquish Funding Convertible Note - 2
On
September 24, 2026, the Company entered into a securities purchase agreement with Vanquish Funding, pursuant
to which the Company issued an unsecured convertible promissory note with an aggregate principal amount of
$
27
Table of Contents
Labrys Convertible Promissory Note
On
July 8, 2026, the Company entered into a Securities Purchase Agreement (the "Labrys SPA") with Labrys Fund II,
L.P. ("Labrys"). Pursuant to the Labrys SPA, the Company issued an unsecured convertible promissory note with
an aggregate principal amount of $
The
Labrys Convertible Promissory Note is convertible into shares of the Company's common stock at the option of
the holder upon the occurrence of certain events specified in the agreement, including the passage of time
following issuance, the occurrence of certain payment defaults, or the effectiveness of a resale registration
statement covering the underlying conversion shares. Upon the occurrence and continuation of an event of
default, amounts outstanding under the Labrys Convertible Promissory Note become immediately due and payable
and are subject to a default amount equal to
After evaluating the terms of the Labrys Convertible Promissory Note, including its conversion, repayment, prepayment, and default provisions, the Company elected the fair value option pursuant to ASC 825, Financial Instruments, which allows the Labrys Convertible Promissory Note and its contractual features to be measured as a single instrument at fair value, eliminating the need to separately assess and account for such features.
Accordingly,
the Labrys Convertible Promissory Note was initially recorded at its fair value of $
As
of September 30, 2026, and December 31, 2025, the fair value of the Labrys Convertible Promissory Note was
$
ADI Promissory Note
As
part of the Settlement Agreement and Mutual Release entered into on July 21, 2026, the Company issued a
promissory note to ADI Funding LLC (the "ADI Promissory Note") with a principal amount of $
Upon
non-payment of the outstanding balance at the maturity date, ADI may convert all or any portion of the
outstanding balance into shares of the Company's common stock at a conversion price equal to
After evaluating the terms of the ADI Promissory Note, including its conversion and default provisions, the Company elected the fair value option pursuant to ASC 825, Financial Instruments. Accordingly, the ADI Promissory Note was initially recorded at fair value and is subsequently remeasured at fair value at each reporting date, with changes in fair value recognized in the condensed consolidated statements of operations.
As
of September 30, 2026, and December 31, 2025, the fair value of the ADI Promissory Note was $
M2B Promissory Note
On April 22, 2026, the Company entered into an Equity Purchase Agreement with M2B Funding Corp. ("M2B") establishing an equity line of credit (the "M2B ELOC"). Under the M2B ELOC, the Company was required to issue commitment shares to M2B. In addition, the Securities Purchase Agreement with ADI Funding, LLC ("ADI") dated June 8, 2026, required the Company, no later than June 11, 2026, to file a registration statement on Form S-1 registering the shares issuable under the M2B ELOC, file a related Current Report on Form 8-K, and deliver irrevocable transfer agent instructions for the issuance of the commitment shares to M2B. The Company did not complete these actions by that date. ADI subsequently delivered a notice of default, and disputes arose with M2B concerning the Company's obligations under the M2B ELOC, including the issuance of the commitment shares and the related registration and SEC disclosure obligations.
On
July 21, 2026, the Company, ADI and M2B entered into a Settlement Agreement and Mutual Release (the
"Settlement Agreement") to resolve these disputes. In exchange for M2B's release of its claims, the Company
issued M2B
28
Table of Contents
Upon
non-payment of the outstanding balance at the maturity date, M2B may convert all or any portion of the
outstanding balance into shares of the Company's common stock at a conversion price equal to
After evaluating the terms of the M2B Promissory Note, including its conversion and default provisions, the Company elected the fair value option pursuant to ASC 825, Financial Instruments. Accordingly, the M2B Promissory Note was initially recorded at fair value and is subsequently remeasured at fair value at each reporting date, with changes in fair value recognized in the condensed consolidated statements of operations.
The
Company evaluated the settlement arrangement and recognized a loss on settlement of approximately $
Other instruments
ELOC / Equity Financing
On
November 21, 2023, DHAC entered into the equity line of credit purchase agreement ("ELOC Agreement") with the
Bridge Investor pursuant to which DHAC may sell and issue to the Bridge Investor, and the Bridge Investor is
obligated to purchase from DHAC, up to $
On
October 18, 2025, the Company terminated the ELOC Agreement. Upon termination, no further shares may be sold
under the ELOC Agreement, and the Company has no remaining obligations under the Equity Purchase Agreement. In
accordance with ASC 815, the termination represents a settlement event, and as such the Company has written
off the ELOC Agreement liability through earnings as of the termination date. The Company recorded a gain on
extinguishment of the ELOC Agreement liability amounting to $
Note 9 Standby Equity Purchase Agreement
June 2026 SEPA
On
June 2, 2026, the Company entered into a Standby Equity Purchase Agreement ("June 2026 SEPA") with YA II PN,
Ltd. (the "Investor"), pursuant to which the Company has the right, but not the obligation, to sell to the
Investor up to $
The
June 2026 SEPA became effective upon execution of the agreement on June 2, 2026.The SEPA liability was
initially recognized at fair value upon issuance. On June 2, 2026, the Company recorded a SEPA liability with
a fair value of $
The
June 2026 SEPA liability is remeasured at fair value at each reporting date, with changes in fair value
recognized in earnings. As of September 30, 2026, the fair value of the June 2026 SEPA liability was $
As of September 30, 2026, no advances had been requested or completed under the SEPA and the June 2026 SEPA remained outstanding and available for future use by the Company, subject to the terms and conditions of the agreement.
Strata SEPA
On
September 2, 2026, the Company entered into a Standby Equity Purchase Agreement (the "Strata SEPA") with
ClearThink Capital Partners, LLC, pursuant to which the Company has the right, but not the obligation, to sell
up to $
29
Table of Contents
The
Strata SEPA became effective upon execution of the agreement. As of September 30, 2026, the Company had not
submitted any purchase notices and no shares had been sold under the facility. Upon issuance, the Company
recorded a loss on issuance of financial instruments of $
The
Strata SEPA liability is remeasured at fair value at each reporting date, with changes in fair value
recognized in earnings. During the three and nine months ended September 30, 2026, the Company recognized a
change in fair value of $(
As of September 30, 2026, the Strata SEPA remained outstanding and available for future use by the Company, subject to the terms and conditions of the agreement.
Note 10 Related Party
Related Party Transactions by iDoc
| (1) | A
related party balance due from the then CEO of iDoc, Imoigele Aisiku, for cash transferred through a company
controlled by him. The balance due from the related party on September 30, 2026, and December 31, 2025, were $
| |
| (2) | iDoc
issued a promissory note on May 15, 2023, with a principal balance of $ |
Related Party Transactions by VSee Health (DHAC)
| (1) | On
November 21, 2023, DHAC entered into a convertible note purchase agreement, pursuant to which an institutional
and accredited investor, the Quantum Investor, subscribed for and purchased, and the Company issued and sold
to the Quantum Investor, after the Closing of the Business Combination on June 25, 2024, and as further
amended on July 3, 2024, a |
| (2) | On
June 21, 2024, the Company entered into a Consulting Services Agreement with SCS, LLC (“SCS”), who
is an affiliate of our Sponsor, pursuant to which we shall pay SCS $ | |
| (3) | On
June 24, 2024, DHAC owed the Sponsor and certain Sponsor affiliates $ |
| (4) | On May 31, 2026, the Company entered into and consummated
a Stock Purchase Agreement with Milton Chen, the Company's then co-Chief Executive Officer, Chairman of the Board, and Chief Executive
Officer of VSee Lab, pursuant to which the Company sold all of its equity interests in VSee Lab, to Milton Chen and Milton Chen transferred
to the Company |
30
Table of Contents
Related Party Transactions by VSee Labs
As VSee Labs was divested on May 31, 2026, the following related party transactions are presented solely for historical comparative purposes and relate to VSee Lab prior to its divestiture. (See Note 3 – Discontinued Operations)
| (1) | During
the year ended December 31, 2022, employees subscribed $ | |
| (2) | During
the year ended December 31, 2022, VSee Lab received a loan of $ | |
| (3) | On
March 29, 2023, VSee Lab received a | |
| (4) | On
December 26, 2023, VSee Lab received a |
Note 11 Commitments, Contingencies, and Concentration Risk
Litigation
We are currently involved in, and may in the future be involved in, legal proceedings, claims, and government investigations in the ordinary course of business. These include proceedings, claims, and investigations relating to, among other things, regulatory matters, commercial matters, intellectual property, competition, tax, employment, pricing, discrimination, consumer rights, personal injury, and property rights.
Depending on the nature of the proceeding, claim, or investigation, we may be subject to settlement awards, monetary damage awards, fines, penalties, or injunctive orders. Furthermore, the outcome of these matters could materially adversely affect the Company’s business, results of operations, and financial condition. The outcomes of legal proceedings, claims, and government investigations are inherently unpredictable and subject to significant judgment to determine the likelihood and amount of loss related to such matters. While it is not possible to determine the outcomes, the Company believes based on its current knowledge that the resolution of its pending legal matter described below will not, either individually or in the aggregate, have a material adverse effect on the business, results of operations, cash flows or financial condition.
On
April 21, 2026, Toppan Merrill LLC filed a lawsuit in the Superior Court in the County of Middlesex,
Massachusetts. The plaintiff alleges that the Company owes $
31
Table of Contents
Encompass Purchase Liability
On
January 1, 2022, iDoc acquired
As
of September 30, 2026, and December 31, 2025, the value of purchase liability related to the Encompass
Acquisition agreement was $
Contingencies
During the normal course of business, the Company may be exposed to litigation. When the Company becomes aware of potential litigation, it evaluates the merits of the case in accordance with ASC 450, Contingencies. Litigation and contingency accruals are based on the Company’s assessment, including advice of legal counsel, regarding the expected outcome of litigation or other dispute resolution proceedings. If the Company determines that an unfavorable outcome is probable and the amount of loss can be reasonably estimated, it establishes the necessary accruals.
As of September 30, 2026, the Company has the following contractual commitments:
| (1) | iDoc
entered into a purchase agreement with a vendor to purchase twenty ( | |
| (2) | iDoc
has a promissory note with a principal balance of $ | |
| (3) | On
May 12, 2023, iDoc entered in a partnership agreement with an accredited investor to agree and collaborate in
the development of telepresence robots for telehealth solutions. The investor pledged to pay $ | |
| (4) | On
January 16, 2026, the Company entered into a Stock Purchase Agreement with GoMyRx, Inc. ("GoMyRx") and Go Biz
Holdings, LLC to acquire an approximately |
VSee Health, Inc. Incentive Plan
DHAC
approved and adopted the VSee Health, Inc. 2024 Equity Incentive Plan (the “2024 Plan”) to be
effective as of one day prior to the closing Business Combination. The 2024 Plan provides for an initial share
reserve equal to
Indemnities
The Company generally indemnifies its customers for the services it provides under its contracts and other specified liabilities, which may subject the Company to indemnity claims, liabilities, and related litigation. As of September 30, 2026, and December 31, 2025, the Company was unaware of any material asserted or unasserted claims concerning these indemnity obligations.
32
Table of Contents
Other Matters
The
Company continues to analyze potential sales tax exposure using a state-by-state assessment. In accordance
with ASC 450, Contingencies, the Company estimated and recorded a liability of $
Credit Risk and Major Customers/Supplier Concentration
Financial instruments potentially subject the Company to credit risk concentrations consisting of cash and trade accounts receivables. The Company maintains all its cash in commercial depository accounts, insured by the Federal Deposit Insurance Corporation. At times, cash deposits may exceed federally insured limits. Any loss incurred or lack of access to such funds could have an adverse impact on the Company’s financial condition, results of operations, and cash flows.
In
aggregate, the Company had two customers whose accounts receivable represented
The
Company has one customer whose revenue accounted for approximately
The
Company had three vendors whose accounts payable and accrued liabilities represented
Note 12 Income Taxes
The components of our income (loss) before income taxes were as follows:
| For the nine months ended | ||||||||
| September 30, 2026 | September 30, 2025 | |||||||
| United States | $ | ( | ) | $ | ( | ) | ||
| Total | $ | ( | ) | $ | ( | ) | ||
| For the three months ended | ||||||||
| September 30, 2026 | September 30, 2025 | |||||||
| United States | $ | ( | ) | $ | ( | ) | ||
| Total | $ | ( | ) | $ | ( | ) | ||
The components of income tax expense (benefit) were as follows:
| For the nine months ended | ||||||||
| September 30, 2026 | September 30, 2025 | |||||||
| Continuing operations | $ | $ | ||||||
| Discontinued operations | ||||||||
| Total | $ | $ | ||||||
| For the three months ended | ||||||||
| September 30, 2026 | September 30, 2025 | |||||||
| Continuing operations | $ | $ | ||||||
| Discontinued operations | ||||||||
| Total | $ | $ | ||||||
The Company evaluates and updates the estimated annual effective income tax rate on a quarterly basis based on current and forecasted operating results and tax laws. Consequently, based upon the mix and timing of the Company’s actual earnings compared to annual projections, the effective tax rate may vary quarterly and may make quarterly comparisons not meaningful. The quarterly income tax provision is generally comprised of tax expense on income or benefit on loss at the most recent estimated annual effective tax rate. The tax effect of discrete items is recognized in the period in which they occur at the applicable statutory rate.
For
the nine-month periods ended September 30, 2026, and September 30, 2025, the Company recorded income tax
expense of $
33
Table of Contents
For
the three-month periods ended September 30, 2026, and September 30, 2025, the Company recorded income tax
expense of $
The Company does not have any uncertain income tax positions as of September 30, 2026, and December 31, 2025.
Note 13 Equity
Preferred Stock
The
Company has
Series A Preferred Stock
The Series A Preferred has the following rights and privileges:
Voting
– Series A preferred stockholders are permitted to vote with the same voting rights as common
stockholders in any actions to be taken by the stockholders of the Company, including any action with respect
to the election of directors to the Board of Directors of the Company. With respect to any vote with the class
of Common Stock, each Preferred Share shall entitle the holder thereof to cast that number of votes per share
as is equal to the number of shares of Common Stock into which it is then convertible (subject to the
ownership limitations specified
Dividends – Series A preferred stockholders shall be entitled to receive cumulative participating dividends when and if declared. Dividends are prior and in preference to any declaration or payment of any dividend to the common stockholders of the Company.
Liquidation – In the event of a Liquidation Event, the Holders shall be entitled to receive in cash out of the assets of the Company, whether from capital or from earnings available for distribution to its stockholders (the “Liquidation Funds”), before any amount shall be paid to the holders of any of shares of Junior Stock, but junior with respect to any Senior Preferred Stock then outstanding, an amount per Preferred Share equal to the amount per share such Holder would receive if such Holder converted such Preferred Share into Common Stock immediately prior to the date of such payment.
Conversion
– Series A preferred stock is convertible into common stock at the option of the holder, at any time
after the earlier of (i)
Redemption
– The Company shall have the right to redeem all, or any portion, of the Series A preferred stock then
outstanding at a price equal to
The Company reviewed the Series A Preferred Stock under ASC 480 and ASC 815 and concluded that Series A Preferred Stock did not include any elements that would preclude them from equity treatment and therefore are not subject to the liability treatment under ASC 480 or derivative guidance under ASC 815.
Series B Preferred Stock
The Series B Preferred Stock has the following rights and privileges:
Ranking – The Series B Preferred Stock rank (i) senior to the common stock, and any other class or series of capital stock of the Company creates hereafter, the terms of which specifically provide that such class or series shall rank junior to the Series B Preferred Stock (“Junior Securities”), (ii) on parity with the Company’s outstanding Series A Preferred Stock as well as any class or series of capital stock of the Company created specifically ranking by its terms on parity with the Series B Preferred Stock (“Parity Securities”), and (iii) junior to any class or series of capital stock of the Company hereafter created specifically ranking by its terms senior to the Series B Preferred Stock.
Dividends – Holders of the Series B Preferred Stock participate on dividends and any other distributions of the Company’s assets as if such holder had held the number of shares of common stock acquirable upon complete conversion of the Series B Preferred Stock immediately prior to the date on which a record is taken for such dividend or distribution, subject to certain limitations on beneficial ownership.
34
Table of Contents
Conversion
Rights – The number of shares of common stock into which the Series B Preferred Stock
are convertible (the “Conversion Rate”) is equal to the Stated Value ($
Purchase Rights – If at any time the Company grants, issues or sells any options, convertible securities, or rights to purchase stock, warrants, securities or other property pro rata to all or substantially all of the record holders of any class of Common Stock (the “Purchase Rights”), then each holder of Series B Preferred Stock will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which such holder could have acquired if such holder had held the number of shares of common stock acquirable upon complete conversion of all the Series B Preferred Shares held by such holder immediately prior to the date as of which the record holders of shares of common stock are to be determined for the grant, issue or sale of such Purchase Rights; subject to certain limitations on beneficial ownership.
Automatic
Cancellation – When the gross proceeds received by the holder in connection with the sale
of
Rights Upon Issuance of Other Securities; Adjustment of Conversion Price upon Subdivision or Combination of Common Stock – If the Company at any time subdivides (or combines) one or more classes of its outstanding shares of common stock into a greater (or lesser) number of shares, the Conversion Price will be proportionately reduced (or increased).
Adjustment of Conversion Price – The Company may, with the prior written consent of the holders of Series B Preferred Stock, reduce the Conversion Price to any amount and for any period of time deemed appropriate by the Board of Directors.
Voting Rights – The holders of Series B Preferred Stock are entitled to notice of all stockholder meetings at which holders of common stock shall be entitled to vote. Except as otherwise provided in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, or as otherwise required by Delaware Law, the holders of Series B Preferred Stock shall have no voting rights.
Reservation Requirements – So long as any Series B Preferred Stock remains outstanding, the Company shall at all times reserve not less than such aggregate number of shares of the common stock as shall be issuable (taking into account the adjustments and restrictions of Section 7 of the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock) upon the conversion of the then outstanding shares of Series B Preferred Stock (assuming any such conversions are made without regard to any limitations on conversion set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock).
Liquidation – Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holders of the Series B Preferred Stock shall be entitled to receive out of the assets legally available for distribution to stockholders, prior and in preference to any distribution of any of the assets or surplus funds of the Company to the holders of the common stock and Junior Securities and pari passu with any distribution to holders of Parity Securities, an amount equal to the Stated Value of for each share of Series B Preferred Stock and an amount equal to any accrued and unpaid dividends thereon, and thereafter holders of Series B Preferred Stock shall be entitled to receive out of the assets, whether capital or surplus, of the Company the same amount that a holder of common stock would receive if the Series B Preferred Stock were fully converted (disregarding for such purposes any conversion limitations set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock).
The Company reviewed the Series B Preferred Stock under ASC 480 and ASC 815 and concluded that Series B Preferred Stock did not include any elements that would preclude them from equity treatment and therefore are not subject to the liability treatment under ASC 480 or derivative guidance under ASC 815.
Common Stock
The
Company is authorized to issue
The
Company issued
Stock Options
In
June 2024, the DHAC board of directors and stockholders approved the 2024 Plan. There are currently
The 2024 Plan provides for the grant of stock options, including options that are intended to qualify as “incentive stock options” under Section 422 of the Code, as well as non-qualified stock options. Each award is set forth in a separate agreement with the person who received the award which indicates the type, terms and conditions of the award.
On
December 30, 2025, the Company's stockholders approved the VSee Health, Inc. 2025 Equity Incentive Plan (the
"2025 Plan"). The 2025 Plan provides for an initial share reserve of
As
of September 30, 2026, and December 31, 2025, there was no unrecognized compensation cost. Stock-based
compensation expense of $
35
Table of Contents
Common Stock Issuance Obligation
In
connection with the Business Combination on June 24, 2024, the Company agreed to assume an obligation by iDoc
to issue
As
of September 30, 2026, and December 31, 2025,
Note 14 Warrants
DHAC Assumed Warrants
The Company has analyzed the public warrants, private warrants, Bridge Warrants (as defined below), September 2024 Warrants and the Extension Warrants and determined they are considered to be freestanding instruments and do not exhibit any of the characteristics in ASC 480 and therefore are not classified as liabilities under ASC 480. The warrants meet all of the requirements for equity classification under ASC 815 and therefore are classified in equity. Below is a summary of the warrants issued and outstanding:
| Public | Private | Bridge | Extension | September 2024 Warrants | Pre-funded Warrants | Common Stock Warrants | Total | |||||||||||||||||||||||||
| Outstanding, December 31, 2025 | ||||||||||||||||||||||||||||||||
| Issued | ||||||||||||||||||||||||||||||||
| Exercised | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| Outstanding, September 30, 2026 | ||||||||||||||||||||||||||||||||
| Exercisable, September 30, 2026 | ||||||||||||||||||||||||||||||||
| Weighted Average Exercise Price * | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||
| Weighted Average Remaining Life in Years | - | |||||||||||||||||||||||||||||||
| * |
Public and Private Warrants
As
of September 30, 2026, and December 31, 2025, there are
However, no warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the shares of common stock issuable upon exercise of the warrants and a current prospectus relating to such shares of common stock. Notwithstanding the foregoing, if a registration statement covering the shares of common stock issuable upon exercise of the public warrants is not effective within a specified period following the consummation of the initial business combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to the exemption provided by Section 3(a)(9) of the Securities Act, provided that such exemption is available. If that exemption, or another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis. In the event of such cashless exercise, each holder would pay the exercise price by surrendering the warrants for that number of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the “fair market value” (defined below) by (y) the fair market value. The “fair market value” for this purpose will mean the average reported last sale price of the shares of common stock for the 5 trading days ending on the trading day prior to the date of exercise. The warrants will expire on the fifth anniversary of the completion of an initial business combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.
36
Table of Contents
The
private warrants are identical to the warrants underlying the units in the Initial Public Offering. The
Company may call the warrants for redemption, in whole and not in part, at a price of $
| ● | at any time after the warrants become exercisable; | |
| ● | upon not less than 30 days’ prior written notice of redemption to each warrant holder; | |
| ● | if, and only if, the reported last sale price of the shares of common stock equals or exceeds $1,440 per share (to be adjusted for stock splits, stock dividends, reorganizations and recapitalizations), for any 20 trading days within a 30-trading day period commencing at any time after the warrants become exercisable and ending on the third business day prior to the notice of redemption to warrant holders; and | |
| ● | if, and only if, there is a current registration statement in effect with respect to the shares of common stock underlying such warrants. |
The
exercise price and number of shares of common stock issuable on exercise of the warrants may be adjusted in
certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization,
reorganization, merger or consolidation. However, except as described below, the warrants will not be adjusted
for issuances of shares of common stock at a price below their respective exercise prices. If (x) the
Company issues additional shares of common stock or equity-linked securities for capital raising purposes in
connection with the closing of the initial business combination at an issue price or effective issue price of
less than $
Warrant
holders may elect to be subject to a restriction on the exercise of their warrants such that an electing
warrant holder would not be able to exercise their warrants to the extent that, after giving effect to such
exercise, such holder would beneficially own in excess of
Bridge Warrants
In
connection with the Business Combination, the Company assumed
Extension Warrants
In
connection with the Business Combination, the Company assumed
September 2024 Warrants
On
September 30, 2024, the Company issued
Warrant Exchange Agreement
On
October 29, 2025, the Company also entered into a warrant exchange arrangement with Alta Partners
(“Alta”) relating to holdings of its Public Warrants, which were issued in connection with the
Company’s initial public offering. Pursuant to the arrangement, Alta exchanged a total of
37
Table of Contents
Private Placement with Armistice
On
November 25, 2025, the Company entered into a securities purchase agreement with Armistice Capital
(“Armistice”) pursuant to which Armistice agreed to purchase an aggregate of
During
the nine months ended September 30, 2026, a total of
Note 15 Reportable segment
Historically,
the Company had two reportable segments, Telehealth and Healthcare Technology. These reportable segments
reflect the manner in which the Company's Chief Executive Officer, who serves as the chief operating decision
maker ("CODM"), regularly reviews financial information, allocates resources, and assesses performance. As of
September 30, 2026, the Company’s Chief Executive Officer was the sole CODM. As of December 31, 2025,
the Company’s CODM role was shared between the
Following the disposition of VSee Lab, the Company no longer conducts Healthcare Technology operations, and the results of continuing operations is reported through the Telehealth segment. Therefore, as of September 30, 2026, the Company has one reportable segment: Telehealth Services.
The CODM reviews gross margin and net loss from our reportable segment to evaluate budgets and forecasts, assess actual performance and allocate resources. The CODM’s review focuses on month to month and quarter to quarter changes in these profit measures in order to identify potential future liquidity issues, evaluate performance and need for potential cost reductions and identify potential vendor sourcing changes. The measure of segment assets is reported on the balance sheet as total consolidated assets.
Our reportable segment is described below.
Telehealth Services – The Company provides high-acuity patient care solutions through physician services delivered using a proprietary technology platform. The Company delivers neuro-critical care, tele-critical care, teleradiology and specialty telehealth services to hospital systems, long-term acute care facilities, correctional facilities and other customers, staffed by board-certified intensivists, neurointensivists, neurologists and advanced practice providers on a 24/7 basis.
The accounting policies of our reportable segment is the same as those described in the “Summary of Significant Accounting Policies” for the Company. In addition, the Company currently operates in one primary geographic area (the United States) and as such, the disclosures below are attributable to that geographic area.
The following table summarizes total revenue and significant expense categories and amounts for the Company's reportable segment that aligns with the segment level information that is regularly provided to the CODM:
| For the Three Months Ended | For the Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenues: | $ | $ | $ | $ | ||||||||||||
| Patient fees | ||||||||||||||||
| Telehealth fees | ||||||||||||||||
| Institutional fees | ||||||||||||||||
| Total revenues | $ | $ | $ | $ | ||||||||||||
| Cost of revenues | ||||||||||||||||
| Segment gross margin | $ | $ | $ | $ | ||||||||||||
| Less: | ||||||||||||||||
| Compensation and related benefits | ||||||||||||||||
| General and administrative | ||||||||||||||||
| Interest expense | ||||||||||||||||
| Other segment items, net (1) | ( | ) | ( | ) | ||||||||||||
| Income tax expense | ||||||||||||||||
| Segment operating loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Reconciliation to net loss: | ||||||||||||||||
| Income (loss) from discontinued operations, net of tax | ( | ) | ( | ) | ||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| (1) |
38
Table of Contents
Note 16 Fair Value Measurements
The following tables present fair value information as of September 30, 2026, and December 31, 2025. The Company’s financial liabilities that were accounted for at fair value on a recurring basis indicate the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:
| September 30, 2026, | Fair Value | (Level 1) | (Level 2) | (Level 3) | ||||||||||||
| Liabilities: | ||||||||||||||||
| ADI Funding LLC Convertible Note | $ | $ | $ | $ | ||||||||||||
| ClearThink Capital Partners Convertible Note | $ | $ | $ | $ | ||||||||||||
| Common stock issuance obligation | $ | $ | $ | $ | ||||||||||||
| June 2026 SEPA liability | $ | $ | $ | $ | ||||||||||||
| Strata SEPA liability | $ | $ | $ | $ | ||||||||||||
| Labrys Convertible Promissory Note | $ | $ | $ | $ | ||||||||||||
| M2B Promissory Note | $ | $ | $ | $ | ||||||||||||
| ADI Promissory Note | $ | $ | $ | $ | ||||||||||||
| December 31, 2025 | Fair Value | (Level 1) | (Level 2) | (Level 3) | ||||||||||||
| Liabilities: | ||||||||||||||||
| Quantum Convertible Note, related party | $ | $ | $ | $ | ||||||||||||
| Common stock issuance obligation | $ | $ | $ | $ | ||||||||||||
| May 2025 Convertible Note | $ | $ | $ | $ | ||||||||||||
Measurement
Quantum Convertible Note
The Company established the initial fair value for the Quantum Convertible Note as of June 25, 2024, which was the date the Quantum Convertible Note was funded. As of December 31, 2025, the fair value was remeasured. Accordingly, the Company measured the debt at fair value using Monte Carlo Model (MCM) . The Quantum Convertible Note was converted and fully settled in May 2026. The MCM was used to value the Quantum Convertible Note for the initial periods and subsequent measurement periods. The initial value in excess of proceeds on June 25, 2024, was recognized in the statement of operations under loss on issuance of financial instruments. The change in fair value between December 31, 2025, and September 30, 2026, was recognized in the statement of operations under change in fair value of financial instruments.
The
Quantum Convertible Note was classified within Level 3 of the fair value hierarchy December 31, 2025, due to
the use of unobservable inputs.
| December 31, 2025 | ||||
| Risk-free interest rate | % | |||
| Expected term (years) | ||||
| Volatility | % | |||
| Stock price | $ | |||
Common Stock Issuance Obligation
The Company established the initial fair value for the common stock issuance obligation to certain employees of the historical iDoc entity as of June 24, 2024, the date the Business Combination closed. As of September 30, 2026, and December 31, 2025, the fair value was remeasured. As the obligation is to issue shares of the Company’s common stock, the Company estimated the fair value of the obligation based on the shares of common stock expected to be issued and the closing price of the Company’s common stock on the date of the fair value measurement. As the key inputs into this fair value estimate are observable, the Company classified the common stock issuance obligation within Level 1 of the fair value hierarchy as of September 30, 2026, and December 31, 2025. The change in fair value between December 31, 2025, and September 30, 2026, was recognized as compensation expense within cost of revenues in the condensed consolidated statements of operations.
May 2025 Convertible Note
The Company established the initial fair value for the May 2025 Convertible Note as of May 30, 2025, which was the date the May 2025 Convertible was funded. As of December 31, 2025, the fair value was remeasured. Accordingly, the Company measured the debt at fair value using MCM. This note was converted into shares of the Company's common stock and fully settled in February 2026. The MCM was used to value the May 2025 Convertible Note for the initial periods and subsequent measurement periods. The change in fair value between December 31, 2025, and September 30, 2026, was recognized in the statement of operations under change in fair value of financial instruments.
39
Table of Contents
The
May 2025 Convertible Note was classified within Level 3 of the fair value hierarchy as of December 31, 2025,
due to the use of unobservable inputs.
| December 31, 2025 | ||||
| Risk-free interest rate | % | |||
| Expected term (years) | ||||
| Volatility | % | |||
| Stock price | $ | |||
ADI Funding Convertible Note
The Company established the initial fair value for the ADI Funding Convertible Note as of June 8, 2026, which was the date the ADI Funding Convertible Note was funded. As of September 30, 2026, the fair value was remeasured. Accordingly, the Company measured the debt at fair value using MCM. The MCM was used to value the ADI Funding Convertible Note for the initial periods and subsequent measurement periods. The change in fair value between June 8, 2026, and September 30, 2026, was recognized in the statement of operations under change in fair value of financial instruments.
The
ADI Funding Convertible Note was classified within Level 3 of the fair value hierarchy as of September 30,
2026, due to the use of unobservable inputs.
| September 30, 2026 | ||||
| Risk-free interest rate | % | |||
| Expected term (years) | ||||
| Volatility | % | |||
| Stock price | $ | |||
ClearThink Convertible Note
The Company established the initial fair value for the ClearThink Convertible Note as of June 22, 2026, which was the date the ClearThink Convertible Note was funded. As of September 30, 2026, the fair value was remeasured. Accordingly, the Company measured the debt at fair value using MCM. The MCM was used to value the ClearThink Convertible Note for the initial periods and subsequent measurement periods.
The
ClearThink Convertible Note was classified within Level 3 of the fair value hierarchy as of September 30,
2026, due to the use of unobservable inputs.
| September 30, 2026 | ||||
| Risk-free interest rate | % | |||
| Expected term (years) | ||||
| Volatility | % | |||
| Stock price | $ | |||
June 2026 SEPA liability
The Company established the initial fair value for the June 2026 SEPA liability as of June 2, 2026, which was the date the agreement was entered. As of September 30, 2026, the fair value was remeasured. Accordingly, the Company measured the SEPA liability at fair value using MCM. The MCM was used to value the June 2026 SEPA liability for the initial periods and subsequent measurement periods.
The
June 2026 SEPA liability was classified within Level 3 of the fair value hierarchy as of September 30, 2026,
due to the use of unobservable inputs.
| September 30, 2026 | ||||
| Risk-free interest rate | % | |||
| Expected term (years) | ||||
| Volatility | % | |||
| Stock price | $ | |||
Strata SEPA liability
The Company established the initial fair value for the Strata SEPA liability as of September 2, 2026, which was the date the agreement was entered. As of September 30, 2026, the fair value was remeasured. Accordingly, the Company measured the SEPA liability at fair value using MCM. The MCM was used to value the Strata SEPA liability for the initial periods and subsequent measurement periods.
40
Table of Contents
The
Strata SEPA liability was classified within Level 3 of the fair value hierarchy as of September 30, 2026, due
to the use of unobservable inputs.
| September 30, 2026 | ||||
| Risk-free interest rate | % | |||
| Expected term (years) | ||||
| Volatility | % | |||
| Stock price | $ | |||
Labrys Convertible Promissory Note
The Company established the initial fair value of the Labrys Convertible Promissory Note as of July 8, 2026, which was the issuance date of the note. As of September 30, 2026, the fair value was remeasured. Accordingly, the Company measured the debt at fair value using MCM. The MCM was used to value the Labrys Convertible Promissory Note for the initial periods and subsequent measurement periods.
The
Labrys Convertible Promissory Note was classified within Level 3 of the fair value hierarchy as of September
30, 2026, due to the use of unobservable inputs.
| September 30, 2026 | ||||
| Risk-free interest rate | % | |||
| Expected term (years) | ||||
| Volatility | % | |||
| Stock price | $ | |||
M2B Promissory Note
The Company established the initial fair value of the M2B Promissory Note as of July 21, 2026, which was the issuance date of the note. As of September 30, 2026, the fair value was remeasured. Accordingly, the Company measured the debt at fair value using MCM. The MCM was used to value the M2B Promissory Note for the initial periods and subsequent measurement periods.
The
M2B Promissory Note was classified within Level 3 of the fair value hierarchy as of September 30, 2026, due to
the use of unobservable inputs.
| September 30, 2026 | ||||
| Risk-free interest rate | % | |||
| Expected term (years) | ||||
| Volatility | % | |||
| Stock price | $ | |||
ADI Promissory note
The Company established the initial fair value of the ADI Promissory note as of July 21, 2026, which was the issuance date of the note. As of September 30, 2026, the fair value was remeasured. Accordingly, the Company measured the debt at fair value using MCM. The MCM was used to value the ADI Promissory note for the initial periods and subsequent measurement periods.
The
ADI Promissory note was classified within Level 3 of the fair value hierarchy as of September 30, 2026 due to
the use of unobservable inputs.
| September 30, 2026 | ||||
| Risk-free interest rate | % | |||
| Expected term (years) | ||||
| Volatility | % | |||
| Stock price | $ | |||
41
Table of Contents
Level 3 Changes in Fair Value
The change in the fair value of the Level 3 financial liabilities for the period from December 31, 2025, through September 30, 2026, is summarized as follows:
| Quantum Convertible Note | May 2025 Convertible Note | ADI Funding LLC Convertible Note | ClearThink Capital Partners Convertible Note | June 2026 SEPA liability | Strata SEPA liability | Labrys Convertible Promissory Note | M2B Promissory Note | ADI Promissory Note | Total | |||||||||||||||||||||||||||||||
| Fair value as of December 31, 2025 | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||
| Initial fair value at issuance | ||||||||||||||||||||||||||||||||||||||||
| Conversion | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||
| Interest accrued | ||||||||||||||||||||||||||||||||||||||||
| Change in fair value of financial instruments | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||
| Gain/(Loss) on extinguishment of financial liabilities | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||
| Fair value as of September 30, 2026 | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||
The change in the fair value of the Level 3 financial liabilities for the period from December 31, 2024, through September 30, 2025, is summarized as follows:
| Quantum Convertible Note | Exchange Note | ELOC | September Convertible Note | March 2025 Convertible Note | May 2025 Convertible Note | Total | ||||||||||||||||||||||
| Fair value as of December 31, 2024 | $ | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||
| Initial fair value at issuance | ||||||||||||||||||||||||||||
| Conversion | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||
| Additions to principal | ||||||||||||||||||||||||||||
| Change in fair value of financial instruments | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||
| Fair value as of September 30, 2025 | $ | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||
Transfers
to/from Levels 1, 2 and 3 are recognized at the end of the reporting period in which a change in valuation
technique or methodology occurs. There were
Note 17 Subsequent Events
The Company evaluated subsequent events from the date of the condensed consolidated balance sheets as of September 30, 2026, through the date of the release of the condensed consolidated financial statements.
On
October 1, 2026, the Company received net proceeds of $
On October 14, 2026, the Company entered into a Settlement Agreement and Stipulation with Silverback Capital Corporation to settle certain outstanding obligations through the issuance of shares of the Company’s common stock pursuant to Section 3(a)(10) of the Securities Act of 1933. The settlement was approved by the Circuit Court on August 5, 2026. Refer to Note 5 - Accounts Payable and Accrued Liabilities, for additional information regarding the settlement agreement and related share issuances.
The Company is not aware of any other events or transactions that would require recognition or disclosure in the condensed consolidated financial statements.
42
Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF VSEE HEALTH
The following discussion and analysis provide information that VSee Health’s management believes is relevant to an assessment and understanding of the results of operations and financial of VSee Health, Inc. (“VSee Health” and for purposes of this section only, referred to as the “Company”, “we,” “us” and “our”). The discussion and analysis should be read together with VSee Health’s consolidated financial statements as of and for the three and nine months ended September 30, 2026 and 2025, and the related respective notes thereto. This discussion may contain forward-looking statements based upon VSee Health’s current expectations, estimates and projections that involve risks and uncertainties. Actual results could differ materially from those anticipated in these forward-looking statements due to, among other considerations, the matters discussed under “Risk Factors” in the Annual Report for the year ended December 31, 2025, and the section herein entitled “Cautionary Note Regarding Forward-Looking Statements.
Overview
Prior to June 24, 2024, we were a blank check company incorporated in the State of Delaware organized for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. On June 24, 2024, we completed the Business Combination pursuant to the Business Combination Agreement dated as of November 21, 2023, as amended by the first amendment dated February 13, 2024, and the second amendment dated April 17, 2024 (as amended, the “Business Combination Agreement”) that we entered into with VSee Lab and iDoc. Upon the completion of the Business Combination, we changed our name to “VSee Health, Inc.” and the business of VSee Lab and iDoc became our business. On May 31, 2026, the Company divested VSee Lab by selling 100% of its ownership interest to Milton Chen, the Company’s former co-Chief Executive Officer. Following the divestiture, VSee Lab became an independent standalone business and is no longer a subsidiary of VSee Health. Accordingly, VSee Lab has been classified as a discontinued operation for periods subsequent to the divestiture date, where applicable. (See Note 3 – Discontinued Operations). Mr. Chen also resigned as the Company’s co-Chief Executive Officer and Chairman of the Board of Directors in connection therewith.
We put telehealth software tools in the hands of clinicians to enable them to make changes without programming so that they can achieve the best patient outcomes. We provide our clients with capabilities specifically built to enable them to collaborate with their clinical and non-clinical colleagues, securely coordinate patient care, conduct virtual patient visits including remote physical exam and remote patient monitoring, and an analytical dashboard to manage their entire telehealth operations from patient satisfaction score to patient wait time to staffing allocations. We empower clinicians to create the workflow they want without waiting for IT; where today, most clinicians feel helpless given that IT departments often cannot give clinicians what they want.
Our wholly owned subsidiary iDoc is a high acuity patient care solution providing elite physician services in intensive care units of our major hospital systems and other customers. iDoc delivers neuro-critical care through a proprietary technology platform. iDoc serves a diverse range of customers from large hospital systems to small/micro hospitals, long-term acute care (LTAC) facilities, correctional facilities and others. In addition to the specialization of neuro critical care, iDoc provides general tele-critical care services, and specialty e-consults to large organizations such as correctional facilities. iDoc has an experienced team of board-certified intensivists, neurointensivists, neurologists, and advanced practice providers that treat and coordinate care for acutely ill patients 24/7 in the Neurointensive Care Unit (“NICU”) and Intensive Care Unit (“ICU”) for stroke, brain trauma, spinal cord, and all other neurological conditions. Our Neurocritical care experts will also help develop multidisciplinary plans of care to optimally treat neurological conditions in relation to their overall medical needs. Our Neuro Critical care service delivery will focus on physicians and provider services in tele neurocritical care, epileptology, and tele neurology. In addition to standard interventions, our Neurocritical care experts will offer specific care including monitoring intracranial pressure, cerebral hemodynamic, advanced multimodal neuro monitoring (brain oximetry, cerebral micro dialysis and continuous electroencephalography).
We strive to be the solutions provider of access to the shortage of intensivists across the care continuum utilizing sophisticated telehealth solutions to bridge the care gap. In a post Covid, physician burnout health care system, we aim to provide a solution to physician burnout and to a lack of patient access to quality intensive care. By using the sophisticated leading telehealth software and hardware devices, we provide access to highly skilled physicians in the highest acuity in patient setting, the ICU. We provide elite physician services in the Intensive care units of major hospital systems and other customers. Our core service delivers general critical care, neurology, EEG reading, and neuro critical care through a custom internal virtual health care technology platform. We also serve a diverse range of customers from large hospital systems to small/micro hospitals, to long-term acute care (LTAC) facilities to the federal prison system and others. We connect critically ill patients to high-quality Neurointensivists, general and cardiac intensivists and specialty specific e-consultations and helps to improve outcomes for patients as well as improved productivity and physician burnout while reduced costs for health systems. We have developed a unique quality control program in collaboration with each hospital by development of a hospital specific reporting dashboard to monitor and achieve high-quality critical care quality. In addition, current workflows and protocols are evaluated to adjust to incorporate critical care. Continuous process improvement and readjustment of target metrics with the ICU team to maximize patient safety and improve outcomes.
Implications of Being an Emerging Growth Company
The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012(the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.
43
Table of Contents
Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The Jobs Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
The Company is also a “smaller reporting company,” meaning that either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) the market value of our shares held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. The Company may continue to be a smaller reporting company if either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our shares held by non-affiliates is less than $700 million. The Company may take advantage of certain of the scaled disclosures available to smaller reporting companies.
Performance Factors
We believe that our future performance will depend on many factors, including the following:
The Rapid Transformation of the Telehealth Market
The Telehealth market today is one characterized by rapid transformation, with major customers and hospital systems looking to build or add capabilities and major legacy competitors looking to shore up historical limitations. We believe that the rapid transformation of the telehealth market indicates strong future growth of the market, and our current offerings provide an attractive value proposition to health systems, medical groups, and individual medical practitioners, driving higher market share. We plan to continue to harness our scale to further grow the value proposition of our platform for all stakeholders.
Ability to Expand Within the Market and Attract New Customers
Telehealth is still in its total infancy stages in terms of utilization, scope, and services. Most of the growth is expected within hospital systems, definition, and segmentation structure, and we believe our software platform and services have significant potential. We plan to leverage our industry relationships with government, hospital systems and insurance providers to increase our customer base.
Innovation and New Product Offerings
Despite the rapid advancements in technology, growth in virtual healthcare delivery, and improvement in decision support algorithms and machine learning tools, Telehealth Technology Solutions have not fully penetrated medicine and hospital systems to become the standard methodology of care and represent less than 1% of total healthcare spending according to Grandview Research. Major reasons for Telehealth solutions not capturing its full potential include:
| ● | Many of the existing video and hardware and software used in telehealth are repurposed businesses that are not healthcare specific. | |
| ● | Remote monitoring/diagnostic devices do not readily integrate into telehealth systems limiting doctors real time metrics to enable diagnostics and assessment. | |
| ● | Backend software coordination is not optimized for telehealth use and connectivity, resulting in significant greater complexity and costs for implementation. | |
| ● | The software and code foundations of the early telemedicine companies have major functionality limitations and arduous implementation and incremental coding/connectivity requirements adding significant cost and reducing functionality. |
We believe our technology solutions meet the performance and compliance standards in healthcare, increase the sharing of patient history, files and scheduling are integrated into the video view for doctors, create sophisticated video engagement between patients, staff and doctors and seamlessly integrate patients’ records to provide more comprehensive telehealth care. We believe our ability to invest in new technology and develop new features, modules, and solutions will be critical to our long-term success.
Significant Accounting Policies and Critical Accounting Estimates
We prepare our consolidated financial statements in accordance with U.S. GAAP. The preparation of consolidated financial statements also requires we make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, costs and expenses and related disclosures. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ significantly from the estimates made by our management. To the extent that there are differences between our estimates and actual results, our future financial statement presentation, balance sheet, results of operations and cash flows will be affected. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving our management’s judgments and estimates. Critical accounting policies and estimates are those that we consider the most important to the portrayal of our balance sheet and results of operations because they require our most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effects of matters that are inherently uncertain.
The preparation of our consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the amounts reported in those consolidated financial statements and accompanying notes. Although we believe that the estimates we use are reasonable, due to the inherent uncertainty involved in making those estimates, actual results reported in future periods could differ from those estimates. Our significant accounting policies are described in Note 2 to our Unaudited Condensed Consolidated Financial Statements for the three-month and nine-month period ended September 30, 2026 included elsewhere in this report. Our critical accounting policies are described below.
44
Table of Contents
Revenue Recognition
The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 establishes a principle for recognizing revenue upon the transfer of promised goods or services to customers in an amount that reflects the expected consideration received in exchange for those goods or services. The core principle of ASC 606 is to recognize revenue to depict the transfer of promised goods or services to clients in an amount that reflects the consideration the entity expects to be entitled in exchange for those goods or services.
The Company derives revenue from business services associated with direct tele-physician provider patient fee services, telehealth services and institutional services provided to our clients.
The Company determines revenue recognition in accordance with ASC 606 through the following five steps:
1) Identify the contract with a customer
The Company considers the terms and conditions of its contracts and the Company’s customary business practices in identifying its contracts under ASC 606. The Company determines it has a contract with a customer when the contract has been approved by both parties, it can identify each party’s rights regarding the services to be transferred and the payment terms for the services, it has determined the customer to have the ability and intent to pay, and the contract has commercial substance. The Company applies judgment in determining the customer’s ability and intent to pay, which is based on a variety of factors, including the customer’s payment history or, in the case of a new customer, credit and financial information pertaining to the customer.
The Company also has service contracts with hospitals or hospital systems, physician practice groups, and other users. These customer contracts typically range from two to three years, with an automatic renewal process. The Company either invoices these customers for the monthly fixed fee in advance or at the end of the month, depending on the contract terms.
The contracts typically contain cancellation clauses with advance notice; therefore, the Company does not believe that it has any material outstanding commitment for future revenues beyond one year from the end of a reporting period.
2) Identify the performance obligations in the contract
Performance obligations promised in a contract are identified based on the services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the service either on its own or together with other resources that are readily available, and are distinct in the context of the contract, whereby the transfer of the services is separately identifiable from other promises in the contract. The Company’s contracts typically contain cancellation clauses with advance notice; therefore, the Company does not believe that they have any material outstanding commitments for future revenues beyond one year from the end of a reporting period.
3) Determine the transaction price
The total transaction price is based on the amount to which the Company is entitled to based on the contracts with its customers. The Company believes the quoted transaction prices in the customer contracts represent the stand-alone selling prices for each of the separate performance obligations which are distinct and priced separately within the contract. The transaction price for each service provided is independent and established in the contract and based on the duration of service provided or for a rate for service provided. Fees are established based on the service transferred to the client.
4) Allocate the transaction price to performance obligations in the contract
If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative stand-alone selling price (“SSP”). The determination of a SSP for each distinct performance obligation requires judgment. The Company believes the quoted transaction prices in the customer contracts represent the standalone selling prices for each of the separate performance obligations that are distinct and priced separately within the contract.
5) Recognize revenue when or as the Company satisfies a performance obligation
Revenue is recognized when or as control of the promised goods or service is transferred to the customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services.
Patient Fees Services and Performance Obligation
Patient Fee Services
Patient fees represent a series of distinct services because performance obligations are met when the Company’s physicians provide professional medical services to patients at the client site. The patient benefits from professional services when care is rendered by the Company’s medical professionals. Revenue recognition commences when the Company satisfies its performance obligation to provide professional medical services to patients.
The Company acts as the principal in these arrangements because it controls the medical services before they are transferred to the patient. This control is evidenced by the Company’s primary responsibility for fulfilling the service and its direct authority over the affiliated physicians, including the right to direct their clinical activities and administrative protocols.
Patient Fee Contracts Involving Third-Party Payors
The Company receives payments from patients, third-party payors, and others for patient fee services. Third-party payors reimburse based on contracted rates or billed charges, which are generally lower than billed amounts. The Company determines the transaction price on patient fees based on standard charges for services provided, reduced by adjustments provided to third-party payors, and implicit price concessions provided to uninsured patients. The Company monitors its revenue and receivables from third-party payors and records an estimated contractual allowance to properly account for the differences between billed and collected amounts.
45
Table of Contents
Revenue from third-party payors is presented net of an estimated provision for contractual adjustments. Patient revenues are net of service credits and service adjustments and expected credit losses. These adjustments and implicit price concessions represent the difference between the amount billed and the estimated consideration the Company expects to receive, based on historical collection experience, market conditions and other factors. Although the Company believes that its approach to estimates and judgments as described herein is reasonable, actual results could differ, from estimated amounts and such difference could be material.
All of the Company’s telemedicine contracts for patient reimbursement fees are directly billed to the payors by the Company. The Company earns patient fees by providing high acuity patient care solutions. For patient fees, performance obligations are met when the Company’s physicians provide professional medical services to patients at the client site as this is deemed as transfer of goods and services to respective patients. The patient benefits from the professional services when care is rendered by the Company’s medical professionals. The revenue is determined based on the telemedicine billing code(s) associated with the respective professional service rendered to patients.
The Company earns primarily from reimbursement from the following third-party payors:
Medicare
The Company’s affiliated provider network is reimbursed by the Medicare Part B and Part C programs for certain of the telemedicine services it provides to Medicare beneficiaries. Medicare coverage for telemedicine services is treated distinctly from other types of professional medical services and is limited by federal statute and subject to specific conditions of participation and payment pursuant to Medicare regulations, policies and guidelines, including the location of the patient, the type of service, and the modality for delivering the telemedicine service, among others.
Medicaid
Medicaid programs are funded jointly by the federal government and the states and are administered by states (or the state’s designated managed care or other similar organizations) under approved plans. Our affiliated provider network is reimbursed by certain State Medicaid programs for certain of the telemedicine services it provides to Medicaid beneficiaries. Medicaid coverage for telemedicine services varies by state and is subject to specific conditions of participation and payment.
Commercial Insurance Providers
The Company is reimbursed by commercial insurance carriers. The basis for payment to the commercial insurance providers is consistent with Medicare reimbursement fee structure guidelines and the Company is in-network or out-of-network with the commercial insurance carriers based on state and insurer requirements.
Telehealth Fees Service Contracts and Performance Obligation
Contract For Telemedicine Care Services
Performance obligations in the contract for telemedicine care are based on services provided via the use of hardware and software integration that includes multi-participant video conferencing, and electronic communication for 24 hours per day, seven days per week for the duration of the contract. The Company provides administrative support for the tele-physician services and coordinates the services of its clinicians’ network through administrative support, hardware support, and software support and provider coverage availability. The Company provides coverage availability of its physician services ranging from 12 to 24 hours per day. Performance obligations in the contract for these services transferred to the customer are distinct in the context of the contract, whereby the transfer of the services is separately identifiable from patient services and institutional services obligations. Performance obligations are met when the Company provides administrative, business, and medical records and reports related to their professional services rendered pursuant to the agreement in such format and upon such interval as hospitals may require. Revenue from telemedicine care services is included in telehealth fees in the condensed consolidated financial statements.
The Company recognizes revenue for variable consideration when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The Company estimates the amount of revenue to be recognized on variable consideration, using the expected value or the most likely amount method, whichever is expected to better predict the amount. The Company’s estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on assessments of legal enforceability, performance, and all information that is reasonably available to the Company. The determination of the amount of revenue the Company can recognize each accounting period requires management to make estimates and judgments on the estimated expected customer life or expected performance period.
The Company commences revenue recognition when the Company satisfies its performance obligation to provide the contractual tele-physician hours services. Prior to the commencement of services, customers generally make initial start-up nonrefundable payments to the Company when contracting for Company training, hardware and software installation and integration, which includes a onetime setup of software security, API interfaces, and compatibility between existing hospital equipment and hardware and software. The Company recognizes revenue upon completion of the implementation when the performance obligation of equipment setup and initial training is completed. The start-up fees do not significantly modify or customize the other goods in the contract. As the start-up service primarily covers initial administrative services for which the Company’s clients can cancel future services upon completion, management considers it to be separable from the ongoing business services, and the Company records start-up fees as revenue when the start-up service is completed over time, using the input method to measure progress each financial period.
Institutional Fees Service Contracts and Performance Obligation
Contract For Electroencephalogram (“EEG”) Professional Interpretation Services
Performance obligations in the contract for EEG professional interpretation services are based on the number of professional services EEG interpretation the Company provides. The performance obligation in the contract for these services transferred to the customer is distinct in the context of the contract, whereby the transfer of the services is separately identifiable from other promises in the contract. To facilitate the delivery of the EEG professional interpretation services, the Company’s physicians use EEG telemedicine equipment provided by the Company. The performance obligation is satisfied based on the number of EEG professional interpretations performed by the Company’s physicians. The number of professional interpretations is traced monthly by both parties and used to determine the revenue earned based on established contractual rates and is included in institutional fees in the condensed consolidated financial statements.
46
Table of Contents
Under most of the Company’s contracts, including contracts with its two top customers, the customer pays fixed monthly fees for telemedicine consultation services, EEG professional interpretation services, platform software services, and hardware fees. The fixed monthly fee provides for a predetermined number of daily, monthly, or annual physician hours of coverage and agreed-upon rates for interpretation and software services. To facilitate the delivery of the consultation services, the facilities use telemedicine equipment and the Company’s virtual healthcare platform, which is provided and installed by the Company. The Company also provides the hospitals with user training, maintenance and support services for the telemedicine equipment used to perform the consultation services.
The Company commences revenue recognition on EEG professional interpretation services when the Company satisfies its performance obligation to provide professional interpretation monthly.
Fair Value of Financial Instruments
“Fair value” is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. ASC 820 establishes a fair value hierarchy that prioritizes and ranks the level of observability of inputs used to measure investments at fair value. The observability of inputs is impacted by a number of factors, including the type of investment, characteristics specific to the investment, market conditions and other factors. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Investments with readily available quoted prices or for which fair value can be measured from quoted prices in active markets will typically have a higher degree of input observability and a lesser degree of judgment applied in determining fair value.
See Note 16 - Fair Value Measurements of the financial statements for additional information on assets and liabilities measured at fair value.
Goodwill
Goodwill represents the excess of purchase price in a business combination over the fair value of the net identifiable assets acquired. We evaluate goodwill for impairment at the reporting unit level by assessing whether it is more likely than not that the fair value of a reporting unit exceeds it carrying value. If this assessment concludes that it is more likely than not that the fair value of a reporting unit exceeds its carrying value, then goodwill is not considered impaired and no further impairment testing is required. Conversely, if the assessment concludes that it is more likely than not that the fair value of a reporting unit is less than it carrying value, a goodwill impairment test is performed to compare the fair value of the reporting unit to its carrying value. The Company determines fair value of the reporting unit using both income and market-based models. Our models contain significant assumptions and accounting estimates about discount rates, future cash flows, and terminal values that could materially affect our operating results or financial position if they were to change significantly in the future and could result in an impairment. We perform our goodwill impairment assessment whenever events or changes in facts or circumstances indicate that impairment may exist and during the fourth quarter each year. The cash flow estimates and discount rates incorporate management’s best estimates, using appropriate and customary assumptions and projections at the date of evaluation. For the three and nine months ended September 30, 2026, the Company performed qualitative analysis by assessing that no adverse economic, industry, operational, or regulatory indicators were identified that would suggest impairment. Based on the qualitative assessment of relevant factors, the Company concludes that no impairment indicators exist determined that there were no triggering events that required the Company to perform a quantitative analysis.
Impairment of Long-lived and Intangible Assets Other than Goodwill
In accordance with ASC 360-10, the Company, on a regular basis, reviews the carrying amount of long-lived assets, including fixed assets, right-of-use assets and intangible assets, for the existence of facts or circumstances, both internally and externally, that suggest impairment. The Company determines if the carrying amount of a long-lived asset is impaired based on anticipated undiscounted cash flows, before interest, from the use of the asset. In the event of impairment, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the asset. Fair value is determined based on the appraised value of the assets or the anticipated cash flows from the use of the asset, discounted at a rate commensurate with the risk involved.
Income Taxes
Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax basis and operating loss, capital loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits as a component of general and administrative expenses. The Company’s federal tax return and any state tax returns are not currently under examination.
The Company applies ASC 740-10, Accounting for Income Taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually from differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.
47
Table of Contents
Financial Statement Components
Three Months Ended September 30, 2026, and 2025 Results of Operations
The following table presents VSee Health’s results of operations for the three months ended September 30, 2026, and 2025:
| 2026 | 2025 | Change | % | |||||||||||||
| Total revenues | $ | 1,496,779 | $ | 2,318,922 | (822,143 | ) | -35 | % | ||||||||
| Cost of revenues | 1,186,100 | 1,187,296 | (1,196 | ) | 0 | % | ||||||||||
| Gross margin | 310,679 | 1,131,626 | (820,947 | ) | -73 | % | ||||||||||
| Total operating expenses | 2,480,497 | 2,951,759 | (471,262 | ) | -16 | % | ||||||||||
| Total other income (expense), net | (678,883 | ) | 1,777,677 | (2,456,560 | ) | -138 | % | |||||||||
| Loss from continued operations before provision for income taxes | (2,848,701 | ) | (42,456 | ) | (2,806,245 | ) | 6610 | % | ||||||||
| Provision for income taxes for continuing operations | - | - | - | 0 | % | |||||||||||
| Income(loss) from continuing operations | $ | (2,848,701 | ) | $ | (42,456 | ) | (2,806,245 | ) | 6610 | % | ||||||
Nine Months Ended September 30, 2026, and 2025 Results of Operations
The following table presents VSee Health’s results of operations for the nine months ended September 30, 2026, and 2025:
| 2026 | 2025 | Change | % | |||||||||||||
| Total revenues | $ | 4,937,956 | $ | 4,571,727 | 366,229 | 8 | % | |||||||||
| Cost of revenues | 3,693,712 | 2,014,819 | 1,678,893 | 83 | % | |||||||||||
| Gross margin | 1,244,244 | 2,556,908 | (1,312,664 | ) | -51 | % | ||||||||||
| Total operating expenses | 7,770,921 | 7,480,174 | 290,747 | 4 | % | |||||||||||
| Total other income (expense), net | (660,992 | ) | (647,024 | ) | (13,968 | ) | 2 | % | ||||||||
| Loss from continued operations before provision for income taxes | (7,187,669 | ) | (5,570,290 | ) | (1,617,379 | ) | 29 | % | ||||||||
| Provision for income taxes for continuing operations | (5,260 | ) | (15,233 | ) | 9,973 | -65 | % | |||||||||
| Income(loss) from continuing operations | $ | (7,192,929 | ) | $ | (5,585,523 | ) | (1,607,406 | ) | 29 | % | ||||||
Revenue
We generate revenue through management and administrative services contracts with hospitals and hospital systems to provide telehealth physician services, teleradiology services, and acute care patient services. We also generate revenue by directly billing insurance companies for care provided at hospitals and hospital systems. Revenue streams include telehealth fees, patient fees, teleradiology fees, and institutional fees. These contracts typically range from two to three years and are subject to automatic renewal.
Revenue was $1,496,779 and $4,937,956 for the three and nine months ended September 30, 2026, respectively, compared to $2,318,922 and $4,571,727 for the corresponding periods in 2025, representing (decreases)/increases of $(822,143), or (35)%, and $366,229, or 8%, respectively. The increases were primarily driven by growth in telehealth fees and patient fees.
Patient fee revenue decreased by $278,065, or 32%, to $604,464 for the three months ended September 30, 2026, compared to $882,529 for the three months ended September 30, 2025. The decrease was primarily attributable to the cessation of Virtual Neuro insurance billings after March 2026, which contributed approximately $217,000 in revenue during the prior-year quarter but did not recur in the current-year period. Patient fee revenue from core insurance services also declined modestly compared to the prior-year period.
For the nine months ended September 30, 2026, patient fees increased by $17,331, or 1%, to $2,086,896 from $2,069,565 for the comparable prior-year period. The increase was driven primarily by higher monthly patient fee revenue during 2026, including revenue associated with Virtual Neuro billing, partially offset by a $503,000 decrease in Virtual Neuro revenue following the reclassification of billings from patient fees to insurance fees after March 2026. Additionally, miscellaneous revenue decreased by $9,177 due to a one-time MedCenter Patients item recognized in February 2025 that did not recur in 2026.
Telehealth fees decreased by $544,078, or 37%, to $892,315 for the three months ended September 30, 2026, from $1,436,393 for the comparable prior-year period. The decrease was primarily attributable to the absence of Tele-ICU revenue in the current-year period following the expiration of the Piedmont Atlanta Neuro ICU and VIBRA Houston coverage contracts, which contributed approximately $443,000 of revenue during the prior-year quarter. The decrease was further impacted by a decline of approximately $87,000 in teleradiology revenue and a decrease of approximately $32,000 in platform hardware and software fees related to the same customer attrition. These decreases were partially offset by an increase of approximately $18,000 in prison telehealth revenue resulting from higher service volumes.
48
Table of Contents
For the nine months ended September 30, 2026, telehealth fees increased by $351,398, or 14%, to $2,851,060 from $2,499,662 for the comparable prior-year period. The increase was driven primarily by higher teleradiology revenue, reflecting a full nine months of operations during 2026 compared to only four months during the prior-year period, including increased activity from University Hospital and the addition of new Select Specialty Hospital locations. Telehealth revenue also benefited from higher prison telehealth service volume. These increases were partially offset by the loss of Tele-ICU revenue following the expiration of the Piedmont Atlanta Neuro ICU and VIBRA Houston coverage contracts, as well as lower platform hardware and software revenues associated with those contracts.
As a result of these factors, revenue decreased by 35% and increased by 8% for the three and nine months ended September 30, 2026, respectively, compared to the corresponding periods in 2025.
Cost of Goods Sold
Cost of revenues consists primarily of physician contractor fees, personnel-related costs for clinical and operational support teams, costs associated with teleradiology services, and other costs directly associated with the delivery of telehealth and patient care services.
Cost of revenues was $1,186,100 and $3,693,712 for the three and nine months ended September 30, 2026, respectively, compared to $1,187,296 and $2,014,819 for the corresponding periods in 2025, respectively, representing a (decrease)/increase of $(1,196), or (0)%, and $1,678,893, or 83%, respectively.
Cost of revenues remained relatively consistent at approximately $1.2 million for the three months ended September 30, 2026, compared to the prior-year period. The composition of cost of revenues changed significantly, however, driven by an increase of approximately $164,000 in medical independent contractor fees associated with the Company's Infinity Teleradiology services, which utilize contracted radiologists to provide diagnostic interpretations. This increase was substantially offset by a decrease of approximately $166,000 in clinical salaries and wages, reflecting the transition of clinical service delivery from internally employed personnel to independent contractors.
For the nine months ended September 30, 2026, cost of revenues increased by approximately $1.68 million, or 83%, compared to the prior-year period. The increase was primarily attributable to approximately $2.26 million of higher medical independent contractor fees associated with the expansion of the Company's Infinity Teleradiology services. Infinity Teleradiology operated for a full nine-month period during 2026, compared to only the period from July through September in the prior year. The increase was partially offset by a decrease of approximately $518,000 in clinical salaries and wages as service delivery shifted toward contracted providers, as well as a decrease of approximately $66,000 in peripheral device costs.
Gross profit decreased by $820,947, from $1,131,626 to $310,679, for the three months ended September 30, 2026, and decreased by $1,312,664, from $2,556,908 to $1,244,244, for the nine months ended September 30, 2026. As a result, gross margin declined to 21% and 25% for the three- and nine-month periods, respectively, from 48% and 55% in the comparable prior-year periods. The decrease was primarily attributable to a change in revenue mix, as higher-margin Tele-ICU and Virtual Neuro revenues were replaced by Infinity Teleradiology services. While teleradiology contributed significantly to revenue growth during 2026, the service line utilizes third-party providers and carries a higher direct cost structure than the Company's legacy Tele-ICU offerings. In addition, the loss of certain Tele-ICU contracts during 2025 reduced the contribution of higher-margin revenue streams, further impacting overall profitability.
Operating Expenses
Operating expenses include all operating costs not included in cost of revenues. These costs consist of compensation and related benefits and general and administrative expenses composed primarily of payroll and payroll-related expenses, professional fees, insurance, software costs, occupancy expenses, depreciation and amortization, and other costs related to the administration of our business.
Operating expenses were $2,480,497 and $7,770,921 for the three and nine months ended September 30, 2026, respectively, compared to $2,951,759 and $7,480,174 for the corresponding periods in 2025, representing a (decrease)/increase of $(471,262), or (16)%, and $290,747, or 4%, respectively.
General and administrative expenses increased by $302,452, or 4%, to $6,425,055 for the nine months ended September 30, 2026, from $6,122,603 for the comparable prior-year period. The increase was primarily driven by higher bad debt expense of approximately $748,000, increased business consulting expenses of approximately $434,000, higher legal fees of approximately $284,000, increased advisory fees of approximately $142,000, and higher investor relations costs of approximately $132,000. These increases were partially offset by decreases in audit fees of approximately $772,000, accounting fees of approximately $240,000, franchise tax expense of approximately $134,000, tax-related fees of approximately $113,000, lease and rental expense of approximately $106,000, and factoring fees of approximately $80,000.
Compensation and related benefits decreased by $11,705, or 0%, to $1,345,866 for the nine months ended September 30, 2026, from $1,357,571 for the comparable prior-year period. The decrease was primarily attributable to lower executive compensation expense, including the settlement of previously accrued salary liabilities, and lower employee benefit costs. These decreases were partially offset by higher salaries, bonus expense, contractor costs, and payroll service fees incurred during the current-year period.
Other Income (Expense)
Other income (expense), net, was $(678,883) and $(660,992) for the three and nine months ended September 30, 2026, respectively, compared to $1,777,677 and $(647,024) for the corresponding periods in 2025. This represents an increase in expense of $(2,456,560), or (138)%, for the three-month period and an increase in expense of $(13,968), or (2)%, for the nine-month period.
For the three months ended September 30, 2026, other expense was $678,883, consisting primarily of a $296,689 loss recognized on the extinguishment of financial liabilities in connection with debt settlement and modification activities, a $164,288 loss related to the issuance of financial instruments, and a $150,403 loss from changes in the fair value of financial instruments. The Company also incurred interest expense of $67,503 during the period.
49
Table of Contents
For the nine months ended September 30, 2026, other expense remained relatively consistent with the comparable prior-year period. The current-year period benefited from a $1,420,000 reduction in interest expense, primarily due to the retirement, conversion, and settlement of various debt instruments. This favorable impact was largely offset by the absence of the $1,410,000 million gain recognized in the prior-year period from changes in the fair value of financial instruments. In addition, the current-year period included a $309,462 loss on the issuance of financial instruments and a $182,504 loss from changes in the fair value of financial instruments, partially offset by a $71,120 gain on the extinguishment of financial liabilities compared to a $126,125 loss recognized in the prior-year period.
Net Loss
Net loss from continuing operations was $2,848,701 and $7,192,929 for the three and nine months ended September 30, 2026, respectively, compared to $42,456 and $5,585,523 for the corresponding periods in 2025. Net loss increased by $2,806,245 for the three-month period, primarily due to lower gross profit resulting from the shift in revenue mix from higher-margin Tele-ICU and Virtual Neuro services to lower-margin teleradiology services, as well as the recognition of losses related to the settlement of the ELOC and the extinguishment of financial liabilities during the current-year period. For the nine-month period, net loss increased by $1,607,406, primarily due to lower gross profit driven by the increased proportion of lower-margin teleradiology services within the Company's revenue mix and higher operating expenses, including increased bad debt, consulting, legal, and investor relations costs. These unfavorable impacts were partially offset by lower interest expense resulting from reduced outstanding debt balances and a gain on extinguishment of financial liabilities recognized during the current-year period.
Cash Flows
The following table presents selected captions from VSee Health’s consolidated statements of cash flows for the nine months ended September 30, 2026, and 2025:
| For the nine months ended | ||||||||
| September 30, | ||||||||
| 2026 | 2025 | |||||||
| Net cash used in operating activities - continuing operations | $ | (2,996,674 | ) | $ | (1,124,839 | ) | ||
| Net cash used in investing activities - continuing operations | (102,288 | ) | - | |||||
| Net cash (used in) provided by financing activities - continuing operations | (760,450 | ) | 1,689,052 | |||||
| Change in cash due to continuing operations | $ | (3,859,412 | ) | $ | 564,213 | |||
| Change in cash due to discontinued operations | (1,150,367 | ) | (417,569 | ) | ||||
| NET CHANGE IN CASH | $ | (5,009,779 | ) | $ | 146,644 | |||
Our principal sources of liquidity are cash and cash equivalents, totaling $41,666 and $472,759 as of September 30, 2026, and 2025, respectively.
Our future capital requirements will depend on many factors, including our growth rate, contract renewal activity, number of subscription renewals, the continuing market acceptance of telehealth, and debt funding.
Cash Used in Operating Activities
Cash used in operating activities from continuing operations was $2,996,674 for the nine months ended September 30, 2026, compared to $1,124,839 for the nine months ended September 30, 2025. The increase in cash used was primarily attributable to a net loss from continuing operations of $7,192,929 in 2026, partially offset by non-cash adjustments of $4,067,963. Changes in operating assets and liabilities resulted in a net cash inflow of approximately $128,292 during the 2026 period.
Cash Used in Investing Activities
Cash used in investing activities from continuing operations was $102,288 for the nine months ended September 30, 2026, compared to $0 for the nine months ended September 30, 2025. The cash outflow in 2026 was primarily attributable to the purchase of long-term investments.
Cash (Used in) Provided by Financing Activities
Cash used in financing activities from continuing operations was $760,450 for the nine months ended September 30, 2026, compared to cash provided by financing activities of $1,689,052 for the nine months ended September 30, 2025. During the nine months ended September 30, 2026, financing cash outflows consisted primarily of repayments of notes payable of $969,864, payments on financing lease liabilities of $591,118, repayments under the line of credit of $348,952, and payments related to the Encompass acquisition liability of $50,000. These outflows were partially offset by proceeds from convertible notes issued of $1,041,000, proceeds from notes issued during the period of $157,500, and proceeds from pre-funded warrants, net of issuance costs, of $984. For the nine months ended September 30, 2025, financing cash inflows consisted primarily of proceeds from notes issued during the period of $1,907,791, proceeds from the issuance of common stock of $541,184, These inflows were partially offset by $10,000, $56,787, $25,000, $44 and $668,092 of payments to shareholder, for factoring payables, on financing lease liability, due on acquisition purchase and repayment on note payable.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
As a smaller reporting company, we are not required to provide the information required by this item.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Disclosure controls are procedures that are designed with the objective of ensuring that information required to be disclosed in our reports filed under the Exchange Act, such as this Report, is recorded, processed, summarized, and reported within the time period specified in the SEC’s rules and forms. Disclosure controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management, including the chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management evaluated, with the participation of our current chief executive officer and chief financial officer (our “Certifying Officers”), the effectiveness of our disclosure controls and procedures as of September 30, 2026, pursuant to Rule 13a-15(b) under the Exchange Act. Based upon that evaluation, our Certifying Officers concluded that, as of September 30, 2026, our disclosure controls and procedures were not effective.
50
Table of Contents
Management concluded that material weaknesses in internal control over financial reporting existed relating to the lack of sufficient number of personnel within the accounting function to adequately segregate duties, we did not have a designed and implemented effective Information Technology General Controls (“ITGC”) related to access controls to financial accounting system, we did not have a formalized control environment and oversite of controls over financial reporting, and we lack proper accounting for significant or non-recurring transactions. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.
We lack the resources to employ additional personnel to help mitigate these material weaknesses and we foresee that these material weaknesses will not be remediated until we receive additional funding to support our accounting department.
We cannot assure you that these or other measures will fully remediate the material weakness in a timely manner. Notwithstanding the identified material weakness, our management believes that the consolidated financial statements included in this report fairly represent in all material respects our financial condition, results of operations and cash flows at and for the periods presented in accordance with U.S. GAAP.
We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Subsequent to the quarter end, in light of the material weakness as described above, we have enhanced our processes to identify and appropriately apply applicable accounting requirements to better evaluate and understand the nuances of the complex accounting standards that apply to our financial statements on a timely basis. Our plans at this time include providing enhanced access to accounting literature, research materials and documents and increased communication among our personnel and third-party professionals with whom we consult regarding application and financial reporting. The elements of our remediation plan can only be accomplished over time, and we can offer no assurance that these initiatives will ultimately have the intended effects.
51
Table of Contents
PART II — OTHER INFORMATION
Item 1. Legal Proceedings
We are from time to time subject to claims, lawsuits and other legal and administrative proceedings arising in the ordinary course of business. Defending such proceedings is costly and can impose a significant burden on management and employees. The results of any future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. We are not presently a party to any litigation the outcome of which, we believe, if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, cash flows or financial condition.
On April 21, 2026, Toppan Merrill LLC filed a lawsuit in the Superior Court in the County of Middlesex, Massachusetts. The plaintiff alleges that the Company owes $845,891 for services rendered by the plaintiff. The plaintiff is also seeking a preliminary injunction enjoining the Company from disposing assets outside of the ordinary course of business. The Company intends to vigorously defend itself against these allegations. The Company has accrued an amount it believes to be reasonable related to this matter based on the services reflected in its accounts payable balance, which differs from the amount claimed by the plaintiff.
Item 1A. Risk Factors
In addition to the other information set forth in this report, you should carefully consider the risk factors discussed in “Part I, Item 1A. Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in “Part II, Item 1A. Risk Factors” of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which could materially affect our business, financial condition, or future operating results and cash flows. We do not believe that there have been any material changes to the risk factors disclosed in “Part I, Item 1A. Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in “Part II, Item 1A. Risk Factors” of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. The risks described in “Part I, Item 1A. Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, in “Part II, Item 1A. Risk Factors” of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and other reports we file with the SEC are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem immaterial also may materially adversely affect our business, financial condition, operating results and/or cash flows.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Other than as described in our Current Reports on Form 8-K filed with the SEC on July 7, 2026, July 24, 2026, July 31, 2026, September 9, 2026, and September 30, 2026, for this fiscal quarter ended September 30, 2026, there were no unregistered securities to report which have not been previously included in a Quarterly Report on Form 10-Q, Annual Report on Form 10-K, or a Current Report on Form 8-K.
52
Table of Contents
Item 3. Defaults Upon Senior Securities
Not applicable.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
During
the three months ended September 30, 2026, none of our directors or officers (as defined in Rule 16a-1(f) of
the Exchange Act) informed us of the
Item 6. Exhibits
The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.
| Exhibit No. | Description | |
| 3.1 | Second Amended and Restated Certificate of Incorporation of VSee Health, Inc. (incorporated by reference to Exhibit 3.1 filed with the Form 8-K filed by the Registrant on June 28, 2024). | |
| 3.2 | Certificate of Designation of Series A Convertible Preferred Stock of VSee Health, Inc. (incorporated by reference to Exhibit 3.2 filed with the Form 8-K filed by the Registrant on June 28, 2024). | |
| 3.3 | Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock, dated December 5, 2025 (incorporated by reference to Exhibit 3.1 filed with the Form 8-K filed by the Registrant on December 11, 2025). | |
| 3.4 | Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of VSee Health, Inc., dated September 22, 2026 (incorporated by reference to Exhibit 3.1 filed with the Form 8-K filed by the Registrant on September 23, 2026). | |
| 3.5 | Amended and Restated Bylaws of VSee Health, Inc. (incorporated by reference to Exhibit 3.3 filed with the Form 8-K filed by the Registrant on June 28, 2024). | |
| 3.6 | Amendment No. 1 to the Amended and Restated Bylaws of VSee Health, Inc. (incorporated by reference to Exhibit 3.1 filed with the Form 8-K filed by the Registrant on December 18, 2025). | |
| 10.1 | Settlement and Mutual Release, dated July 21, 2026, by and among ADI Funding LLC and M2B Funding Corp. (incorporated by reference to Exhibit 10.80 filed with the Form S-1 filed by the Registrant on October 1, 2026). | |
| 10.2 | Settlement Promissory Note (ADI), dated July 21, 2026 (incorporated by reference to Exhibit 10.81 filed with the Form S-1 filed by the Registrant on October 1, 2026). | |
| 10.3 | Settlement Promissory Note (M2B), dated July 21, 2026 (incorporated by reference to Exhibit 10.82 filed with the Form S-1 filed by the Registrant on October 1, 2026). | |
| 10.4 | Strata Purchase Agreement, dated September 2, 2026, between VSee Health, Inc. and ClearThink Capital Partners, LLC (incorporated by Ference to Exhibit 10.1 filed with the Form 8-K filed by the Registrant on September 9, 2026). | |
| 10.5 | Unsecured Convertible Promissory Note, dated September 24, 2026 (incorporated by reference to Exhibit 10.2 filed with the Form 8-K filed by the Registrant on September 30, 2026). | |
| 31.1* | Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934. | |
| 31.2* | Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934. | |
| 32.1* | Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. § 1350. | |
| 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | |
| 101.SCH | XBRL Taxonomy Extension Schema Document. | |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document. | |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document. | |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document. | |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document. | |
| 104 | Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| * | Filed herewith (furnished herewith with respect to Exhibit 32.1) |
53
Table of Contents
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| VSEE HEALTH, INC. | ||
| Date: November 16, 2026 | By: | /s/ Imoigele Aisiku |
| Name: | Imoigele Aisiku | |
| Title: | Chief Executive Officer and Chairman of the Board | |
| (Principal Executive Officer) | ||
| Date: November 16, 2026 | By: | /s/ Jerry Leonard |
| Name: | Jerry Leonard | |
| Title: | Chief Financial Officer and Secretary | |
| (Principal Financial and Accounting Officer) | ||
54